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Alterations in p53 and Rb tumor suppressors or their pathways are 
common in human breast cancer. We used newly generated MMTV-
Cre105Ayn mice to inactivate p53 and/or Rb strictly in the mammary 
epithelium. Inactivation of p53 led to formation of estrogen receptor positive 
raloxifene-responsive mammary carcinomas with features of luminal subtype 
B. Rb deficiency was insufficient to initiate carcinogenesis but accelerated 
formation of mammary carcinomas in combination with p53 inactivation and 
promoted genomic instability. The recurrent amplification of the cIAP1, cIAP2 
and Yap1 protooncogenes in the 9A1 locus was observed only in neoplasms 
associated with p53 inactivation alone. However, all three genes remained 
overexpressed in carcinomas with p53 and Rb inactivation due to elevated 
E2F expression and cooperated in carcinogenesis. To test involvement of the 
stem cell compartment in the initiation of mammary carcinogenesis we have 
isolated mammary stem cells (MRU; CD24medCD49fhigh), and their progeny 
(Ma-CFC, CD24
high
CD49f
low
). Loss of either p53 or Rb led to an increase in the 
number and proliferation rate of Ma-CFC but not MRU. Both parameters were 
further increased in Ma-CFC pool deficient for both p53 and Rb. Notably, the 
resulting mammary neoplasms contained CD24+CD49f+ cells. Far fewer of 
CD24+CD49f+ cells were required for orthotopic transplantation, as compared 
to CD24-CD49f- cell population. CD24+CD49f+ cells yielded carcinomas much 
 earlier and were able to reconstitute all tumor cell populations more efficiently 
than CD24-CD49f- cells in secondary and tertiary transplantations. Thus, 
CD24+CD49f+ cells meet the definition of cancer stem cells (CSC). We have 
determined that CSC show higher genomic stability and are characterized by 
upregulation of Aldh1, cIAP1 and downregulation of microRNAs miR-376b and 
miR-467b. Importantly we have identified cIAP1 and cIAP2 as targets of both 
miRNAs and shown that miR-376b, miR-467b, cIAP1 and cIAP2 affect stem 
cell properties of CSC. Taken together, these findings establish a model of 
luminal subtype B mammary carcinoma, demonstrate that p53 and Rb 
cooperate in the maintenance of genomic integrity, identify critical role of 
cIAP1, cIAP2 and Yap co-expression in mammary carcinogenesis. 
Furthermore, our studies identify and characterize CSC and uncover miR-
376b/miR-467b - cIAP1/2 pathway as a promising novel target for CSC-
specific therapy. 
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CHAPTER 1 
 
INTRODUCTION* 
 
1.1  Breast cancer etiology and pathogenesis 
It is estimated that, in 2010, there will be a total of 1,529,560 new 
cancer cases and 569,490 cancer-related deaths in the United States, 
accounting for about 23% of all deaths (Jemal et al., 2010). Breast cancer is 
the most commonly diagnosed form of cancer and the second leading cause 
of cancer deaths in western women. One out of eight women will develop 
breast cancer during her lifetime. It is estimated that there will be 
approximately 207,090 new cases in the year 2010 in the U.S. alone (Jemal et 
al., 2010). Although our abilities to detect and treat breast cancer are 
improving, much remains to be understood about the pathogenesis and 
molecular basis of breast cancer. 
The etiology of breast cancer is multifactorial and involves diet, 
reproductive factors, body weight, physical activity and related to hormonal 
imbalances. People with high caloric diet rich in animal fat and proteins, 
combined with a lack of physical exercise show a marked increase in 
incidence and mortality (Tavassoéli and Devilee, 2003). Comparative genomic 
hybridization (CGH) has indentified chromosomal subregions with increased 
DNA copy number, including 1q31-q32, 8q24, 16p13, 17q12, 17q22-24, and 
20q13, and chromosomal subregions with decreased DNA copy number,  
 
*Partially adopted from Cheng L et al., Toxicol Pathol. 2010;38(1):62-71. 
http://tpx.sagepub.com/content/38/1/62.long  
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including 1p32-36, 3p14-21, 7q31, 16q22, 17p13, and 18q21. A numbers of 
oncogenes have been found amplified, including EFGR, FGFR1, c-MYC, 
CCND1, and ERBB2. Some of tumor suppressors have been found based on 
DNA copy number loss, such as IGF2R, ST7, RB1CC1, CDH1, and P53 
(Tavassoéli and Devilee, 2003). Regarding to familial risk of breast cancer, 
studies have found significantly elevated relative risks of breast cancer for 
female relatives of breast cancer patients. BRCA1 and BRCA2 explain about 
20% of the overall familial risk of breast cancer (Tavassoéli and Devilee, 
2003).  
According to World Health Organization histological classification of 
breast tumors (a.k.a. tumors of the mammary gland), the types of breast 
cancer include invasive ductal carcinoma, invasive lobular carcinoma, tubular 
carcinoma, invasive cribriform carcinoma, medullary carcinoma, mucinous 
carcinoma, neuroendocrine tumors, invasive papillary carcinoma, apocrine 
carcinoma, and some other very rare types (Tavassoéli and Devilee, 2003).  
Molecular expression profiling of breast cancers has revealed six main 
subtypes: luminal A, luminal B, luminal C, Erbb2 positive, basal like, and 
normal breast like (Hu et al., 2006; Sorlie et al., 2001; Sotiriou et al., 2003; 
Sotiriou and Pusztai, 2009). Luminal A subtype had the highest expression of 
the estrogen receptor α (ERα) gene, GATA binding protein 3, X-box binding 
protein 1, trefoil factor 3, hepatocyte nuclear factor 3α, and estrogen-regulated 
LIV-1. Luminal B subtype of tumors showed low to moderate expression of the 
luminal-specific genes including the ER cluster. Luminal subtype C was further 
distinguished from luminal subtypes A and B by the high expression of a novel 
set of genes whose coordinated function is unknown, which is a feature they 
share with the basal-like and ERBB2+ subtypes. The ERBB2+ subtype was 
 3 
characterized by high expression of several genes in the ERBB2 amplicon at 
17q22.24 including ERBB2 and GRB7. The basal-like subtype was 
characterized by high expression of keratins 5 and 17, laminin, and fatty acid 
binding protein 7. The normal breast-like group showed the highest expression 
of many genes known to be expressed by adipose tissue and other 
nonepithelial cell types. These tumors also showed strong expression of basal 
epithelial genes and low expression of luminal epithelial genes (Sorlie et al., 
2001; Sotiriou et al., 2003; Sotiriou and Pusztai, 2009). Importantly, p53 
mutations are most frequently associated with basal-like/ER negative (82%) 
ERBB2/HER2+ ER negative (71%) and luminal/ER positive luminal subtype B 
(40%) breast cancers (Sorlie et al., 2001) all of which have poor prognosis (Hu 
et al., 2006; Sorlie et al., 2001). These different subtypes may originate in 
distinct breast epithelial cells, or so called the cell of the origin. Better 
understanding of breast cancer heterogeneity and the nature of tumor initiation 
requires delineation of the mammary epithelial subtypes, including mammary 
stem cell, mammary progenitor cell, myoepithelial and luminal epithelia cells 
(Smalley and Ashworth, 2003). 
 
1.2 Mammary stem cell 
It is now generally accepted that the vast majority of, if not all, tissues 
have rare tissue-specific multipotent adult stem cells. The adult stem cell is 
capable of renewing itself and differentiating into one or more specialized cells 
(reviewed in Fuchs, 2009; reviewed in Orkin and Zon, 2008; Rossi et al., 
2008). Proliferating progeny of stem cells fated for differentiation are usually 
named transit-amplifying cells (Smith, 2006) (Figure 1). At the same time, the  
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Figure 1.1 Cancer stem cell hypothesis.  
Cancer stem cells (CSC, purple) have been defined as a subset of tumor cells 
with stem cell-like properties that are thought to be responsible for the growth, 
progression, metastasis, and recurrence of a tumor. Initiating mutation (yellow 
bolts) can occur in stem cells (red), transit-amplifying cells (blue) and possibly 
even their fully differentiated progeny (green). 
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“progenitor cell” term is commonly used to identify any dividing cell with the 
capacity to differentiate. This includes putative stem cells and transit-amplified 
cells in which presence of long-term self-renewal potential has not yet been 
determined or excluded, respectively.  
Existence of putative mammary stem cells (MaSC) has been postulated 
for years due to the routine tissue renewal and massive expansions in 
epithelial tissue that occur in the mammary gland during pregnancy and 
lactation (Smalley and Ashworth, 2003). Mouse MaSC are thought to give rise 
to either of two progenitor cells, one which gives rise to myoepithelial cells and 
the second which gives rise to luminal cells, and are responsible for much of 
the amplification in cell number that is observed during pregnancy and 
lactation (Smalley and Ashworth, 2003). Recently, considerable progress has 
been made in the field of mammary stem cell biology, and some of 
approaches used in other systems have been applied to the mouse mammary 
gland. The mouse MaSC has been prospectively isolated by Shackleton et al. 
(2006) and Stingl et al. (2006), which give rise the opportunity to investigate 
the cell of origin of mammary cancer. Mammary repopulating units (MRU, 
CD24medCD49fhigh) are MaSC, and their progeny mammary colony-forming 
cells (Ma-CFC, CD24highCD49flow) are mammary progenitors (Stingl et al., 
2006). Cleared mammary fat pad transplantations have been a standard 
technique in mammary gland biology. In this experiment, the mammary 
epithelium is cleared from a young mouse, leaving only the fat pad. Cells 
transplanted into this fat pad can regenerate the lobulo-alveolar mammary tree 
after 4 weeks (Smalley and Ashworth, 2003). 
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1.3 Cancer stem cell 
The concept of cancer stem cells (CSC) or tumor initiating cells can be 
traced back to the “embryonal rest” theory proposed by Conheim and Durante 
in 19th century (reviewed in Sell, 2004). The modern version stipulates that 
CSC represent a subpopulation of neoplastic cells which may be responsible 
for cancer initiation and/or progression (reviewed in Cho and Clarke, 2008; 
Clarke and Fuller, 2006; reviewed in Matoso et al., 2008; Nafus and Nikitin, 
2009; Visvader and Lindeman, 2008; Wicha et al., 2006).  
CSC have stem cell-like properties that include the active expression of 
telomerase and common stem cell genes, the activation of antiapoptotic 
pathways, and an increased ability to migrate and metastasize. Furthermore, 
CSC may remain relatively quiescent and have mechanisms enhancing their 
survival and multi-drug resistance, enabling them to evade traditional cancer 
therapies that target rapidly dividing cells (reviewed in Matoso et al., 2008; 
reviewed in Visvader and Lindeman, 2008). 
It is important to emphasize that the term CSC does not refer to the cell 
of origin. Rather, CSC have been named as such in reference to the 
properties that CSC share with normal stem cells (Wicha et al., 2006). CSC 
may originate from mutated stem, transit-amplifying, or differentiated cells 
(Figure 1). It is also possible that an initial mutation occurs within a stem cell, 
but subsequent mutations occur in its downstream progeny that gain stem cell 
properties during neoplastic transformation and function as CSC.  
Traditionally, CSC have been identified through sphere formation in 
culture with matrigel or extra-low attachment conditions and serial 
transplantation of cellular subpopulation isolated with a Fluorescence 
Activated Cell Sorting (FACS) into animal models (reviewed in Nafus and 
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Nikitin, 2009). Both assays are designed to determine the self-renewal and 
differentiation potential of a cell population and are adapted from adult stem 
cell research, where they have been used to characterize adult stem cells 
(Shackleton et al., 2006) in neural tissues (Doetsch et al., 1999) the prostate 
(Tsujimura et al., 2002; Xin et al., 2003), and the mammary gland (Shackleton 
et al., 2006; Stingl et al., 2006). After transplantation of the CSC population 
and subsequent tumor formation, the primary tumor is expected to mirror the 
phenotypic heterogeneity of the original tumor and exhibit the ability to self-
renewal in serial transplantations. It is commonly anticipated that they have 
higher tumorigenicity as compared to other neoplastic cells (reviewed in Nafus 
and Nikitin, 2009). The tumorigenic potential is usually tested by 
transplantations of serially diluted cell populations.  
To date, in humans, CSC have been identified in a number of 
malignancies, including leukemia (Bonnet and Dick, 1997; Lapidot et al., 
1994), breast cancer (Al-Hajj et al., 2003), prostate cancer (Collins et al., 
2005), brain tumors (Bao et al., 2006), ovarian cancer (Alvero et al., 2009; 
Szotek et al., 2006; Zhang et al., 2008b) and colon cancer (O'Brien et al., 
2007; Ricci-Vitiani et al., 2007) (Table 1). These studies typically rely upon 
xenotransplantation of the CSC subpopulation of a human tumor into mice 
with a compromised immune system (typically non-obese diabetic/severe 
combined immunodeficient (NOD/SCID) mice). Albeit useful, these systems do 
not accurately reflect such critical for carcinogenesis factors as 
microenvironment and the immune response (Frese and Tuveson, 2007). 
Consistent with these limitations of xenotransplantations, a recent study by 
Quintana and colleagues (Quintana et al., 2008) demonstrated that by using 
severely immunocompromised (IL2rγ null NOD/SCID) mice about 25% of  
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unselected melanoma cells formed tumors as compared to 0.1-0.0001% of 
cells able to form tumors in less immunocompromised NOD/SCID mice.  
In animal model, the CSC subpopulation has been described in several  
mouse models of mammary carcinogenesis using different cell surface 
markers (Cho et al., 2008; Vaillant et al., 2008; Zhang et al., 2008a). For 
example, in the MMTV-Wnt1 mouse model of mammary cancer, a 
Thy1+CD24+ cancer cell population was found to be highly enriched for CSC 
relative to the non Thy1+CD24+ population (Cho et al., 2008). In the p53-null 
mammary tumor model described by Zhang and colleagues (Zhang et al., 
2008a), a subpopulation of cells expressing high levels of CD24 and CD29 
(Lin-CD24HCD29H), which accounts for 5-10% of total mammary epithelial cell 
population, has been identified as CSC by limiting dilution in cell culture 
mammosphere assays and subsequent transplantation in vivo. However, it 
should be noted that all experiments in this study were performed on tumors 
derived by transplantation of p53-null mammary epithelium cells into cleared 
mammary fat pads. Thus, it remains to be demonstrated if observed results 
can be reproduced in an autochthonous sporadic mouse model of mammary 
carcinogenesis.  
 
1.4 Tumor suppressor genes p53 and Rb 
             Cancer formation, including breast carcinogenesis, is a multistep 
process. Many of these steps involve inactivation of tumor suppressor genes 
or activation of oncogenes, followed by sequential accumulation of genetic 
alternations (Fialkow, 1974; Nowell, 1976). p53 and Rb are central to these 
processes and they are frequently altered in the breast cancer. p53 is 
evolutionally ancient transcription factor, the primordial function of which in 
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early metazoans may have been to coordinate transcriptional responses to 
stress and damage (Junttila and Evan, 2009). Initially, p53 was considered to 
be a tumor oncogene with transforming abilities. Only during the late 1980s, it 
was revealed that p53 acts as an important tumor suppressor (Nigro et al., 
1989). Since then, evidences demonstrated that either it or its attendant 
upstream or downstream pathways are functionally inactivated in virtually all 
cancers, and 20-40% of sporadic breast carcinomas have mutation in the p53 
gene (Brosh and Rotter, 2009); (Borresen-Dale, 2003). p53 regulates genes 
critical for cell cycle, apoptosis, senescence, and DNA repair, thus preventing 
genomic instability (Meek, 2009, Riley, 2008 #35; Riley et al., 2008). In normal 
unstressed cells, p53 activity is maintained at low levels, which mediates many 
physiological functions. These low levels are primarily maintained by the 
ubiquitin-mediated degradation of p53, a process regulated by E3 ubiquitin 
ligase MDM2 and the related protein MDM4 (Brosh and Rotter, 2009). 
Activation of p53 by DNA damage is principally mediated through post-
translational modification (phosphorylation). The phosphorylation of p53 
impairs interactions between p53 and MDM2 and MDM4, inhibiting the 
capacity of MDM2 and MDM4 to suppress p53 transcription and promote p53 
degradation (Junttila and Evan, 2009).  
          Mice homozygous for the p53 null allele (p53-/-) develop lymphomas or 
sarcomas within the first 3 month after birth (Donehower et al., 1992; Jacks et 
al., 1994). Development of some mammary tumors was observed in p53+/- 
mice, but only on the BALB/c background (Kuperwasser et al., 2000). With the 
development of Cre-LoxP technology, spontaneous mammary tumor 
development was observed after inactivation of wild-type p53 by either its 
deletion (Lin et al., 2004; Liu et al., 2007) or expression of dominant negative 
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form carrying p53.R270H point mutation (Wijnhoven et al., 2005). 
Unfortunately, the interpretation of experiments has been somewhat 
complicated by formation of lymphomas and/or other neoplasms due to 
expression of Cre transgene in lymphocytes and other tissues.  
 Rb is essential for cell cycle control and exerts diverse effects on cell 
proliferation, survival and differentiation (Burkhart and Sage, 2008). More 
recently the role of Rb in control of genomic instability has been demonstrated 
in cell culture experiments and mouse model of liver neoplasia (Reed et al., 
2009; Seeley et al., 2007). Transcription factor E2F family is primary 
downstream effectors of the Rb. In mammals, the E2F family includes eight 
genes (E2F1-8), which give rise to nine different proteins. E2F1, E2F2, and 
E2F3a, which interact only with Rb, are mainly transcription activators and 
have been referred to as activator E2F. E2F4-8 are largely transcription 
repressor and have been referred to as repressor E2Fs. 
The observation that Rb is inactivated in 20-35% of human breast 
cancers suggests that it has an important role in the pathogenesis of these 
neoplasms (Bosco et al., 2007; Scambia et al., 2006). Additionally, other 
defects of Rb pathway components, such as Cyclin D1 overexpression, and 
p16INK4A loss are frequently observed in human breast cancer (Geradts and 
Wilson, 1996; Roy and Thompson, 2006). However, in serial transplantations 
of Rb mutant mammary anlagen no significant differences were found in 
outgrowth of pRb-deficient and wild-type epithelia (Robinson et al., 2001). At 
the same time, transgenic mice expressing cyclin D1 in the mammary gland, 
hence deprived of functional Rb family proteins (Rb, p107 and p130), develop 
mammary neoplasms adenocarcinoma (Wang et al., 1994). Accordingly, It has 
been reported that inactivation of the whole Rb family by T121m a fragment of 
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SV40 T antigen, leads to development of mammary tumors (Simin et al., 
2004). It is known that p107 and p130 could play overlapping roles of Rb in 
many cell types of mouse (Dannenberg et al., 2000; Luo et al., 1998; 
Robanus-Maandag et al., 1998; Sage et al., 2000). Nevertheless, Rb itself 
also has distinct functions that are not compensated by p107 and p130. Unlike 
Rb−/− mice which die during embryonic development (Clarke et al., 1992; 
Jacks et al., 1992; Lee et al., 1992), simultaneous disruption of p107 and p130 
is compatible with embryonic development up to birth (Cobrinik et al., 1996). 
The earlier lethal outcome of germline Rb mutation indicates that Rb 
possesses indispensable functions. Furthermore, Rb family members have 
different binding capacities for E2F-binding sites (Dyson, 1998), indicating 
these genes can repress different subsets of genes. Finally, mutations in Rb 
but not in p107 and p130 genes are found in many types of human cancers 
(Weinberg, 1995). The tumor suppressor function that distinguishes Rb from 
other pocket proteins may originate from the biochemical properties of Rb or 
the nature of the cell in which Rb functions. All these evidences suggest the 
distinct function of Rb. However, the exact function of Rb itself in mammary 
carcinogenesis is still not clear, because of lacking mouse model with 
specifically inactivation of Rb in mammary gland epithelium.  
There is extensive crosstalk between p53 and Rb, which influences vital 
cellular decisions. Rb-E2F acts both upstream and downstream of the Arf-p53 
pathway (Sherr and McCormick, 2002). While the cooperation of p53 and Rb 
in restricting carcinogenesis and activating many apoptotic genes may vary in 
different cellular context. Because mutation of p53 and Rb pathway often 
coexist in human breast carcinoma, to investigate the interactions between Rb 
and p53 signaling pathways in breast epithelial cell are critical for 
 13 
understanding the formation and development of breast cancer. A mouse 
model with conditional loss both p53 and Rb in the mammary epithelium may 
significantly facilitate addressing this issue. 
 
1.5 p53, Rb and stem cells 
To date, p53 has been shown to induce differentiation of embryonic 
stem cells and to limit the capacity of stem cells to self-renew (Lin et al., 2005; 
Qin et al., 2006; Rosso et al., 2006), mediate the onset of senescence of 
endothelial progenitor cells (Rosso et al., 2006) and negatively regulate 
proliferation and survival of neural stem cells (Meletis et al., 2006). More 
recently, it was reported that reducing the activity of p53 in mouse embryonic 
fibroblasts improves the efficiency and kinetics of generating inducing 
pluripotent stem (iPS) cells, even in the absence of Myc retrovirus, and using 
only Oct4 and Sox2 (Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009; 
Marion et al., 2009; Utikal et al., 2009).  
Rb also plays a prominent role in controlling several aspects of stem 
cell biology, including control stem cell cycle progression, senescence and 
tissue homeostasis (Galderisi et al., 2006; Wenzel et al., 2007; Wildwater et 
al., 2005). Mouse fibroblasts lacking Rb function form spheres and undergo 
reprogramming to a cancer stem cell phenotype (Liu et al., 2009). In spite of 
these studies, the potential functions for p53 and Rb in MaSC have not been 
yet addressed. Since p53 and Rb mutations are common in breast carcinoma, 
it is of particular interest to study if molecular mechanisms controlling MaSCs 
self-renewal and mammary cancer initiation and progression are shared.   
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1.6 microRNAs 
microRNAs (miRNAs) are short (around 22 nucleotides) endogenous, 
single-stranded RNA molecules that regulate gene expression. Like 
transcription factors, miRNAs regulate diverse cellular pathways and most 
biological processes. The first miRNA lin-4 (22 nucleotides) was discovered by 
Ambros and colleagues in a screen for genes required for post embryonic 
development in C.elegans in 1993 (Bartel, 2004). The lin-4 locus produces a 
single strand RNA that is partially complementary to sequence in the 3’ 
Untranslated Region (UTR) of its regulatory target, the lin-14 mRNA (Ghildiyal 
and Zamore, 2009). Initially thought to represent a rare class of regulatory 
molecules, the number of identified miRNA is now over 110 in C.elegans, 140 
in the Drosophila, and 400 in humans-numbers that approach about 1-2% of 
the number of protein –coding genes in these respective species (Bartel, 
2009).   
miRNA genes are typically transcribed by RNA polymerase II into 
primary miRNA transcripts (pri-miRNA), and their transcription is sensitive to 
the polymerase II inhibitor α-amanitin treatment. The pri-miRNA is then 
endonucleolytically cleaved by the nuclear micro-processor complex, 
consisting of RNase III enzyme Drosha and the RNA binding protein Pasha, to 
generate a precursor-miRNA (pre-miRNA) which has stem-loop secondary 
structure about 70bp in size (Ghildiyal and Zamore, 2009; Winter et al., 2009). 
Pre-miRNA is exported to the cytoplasm by an exportin-5 mediated complex. 
Once in the cytoplasm, pre-miRNA is cleaved by the RNase III Dicer, 
generating a roughly 22 nucleotide miRNA duplex with two nucleotides 
protruding as overhangs at each 3’ end. Double-strand miRNA needs to be 
separated into functional guides strand, and passenger strand. The mature 
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miRNA (functional guides strand) is selectively recruited into the RNA Induced 
Silencing Complex (RISC). The passenger strand is subsequently degraded. 
This functional asymmetry depends on the thermodynamic stability of the base 
pairs at the two ends of the strand: the miRNA strand with the less stable base 
pair at its 5’ end is loaded into RISC. The RISC-miRNA complex is able to bind 
to the 3’ UTR of target mRNA (Winter et al., 2009).  
The mechanism by which a miRNA regulates its mRNA target reflects 
both the specific Argonaut protein into which the small RNA is loaded and the 
extent of complementarily between the miRNA and the mRNA. Most miRNA 
pair with their targets through only a limited region of sequence nucleotides 2-
8 at the 5’ end of the miRNA are designed the seed sequence. The seed is 
primary specificity determinant for target selection (Bartel, 2009). The 
canonical binding sites are described as 7mer-A1, 7mer-m8, and 8mer, which 
respectively refer to an Adenine at site 1 of the mRNA and matches at 
nucleotides 2-7, 2-8, and 2-8 with an Adenine at site 1. 3’ supplementary of 
compensatory sites may also have a role in predicting the targets of miRNA 
(Bartel, 2009). More often, though, the 3’ end of the miRNA is involved in 
binding with the Argonaut protein that is a part of the RISC13. This information 
was used to develop programming algorithms to create databases for miRNA 
targets based on conservation across species and stringency of seed 
sequence binding to 3’ UTRs (Bartel, 2009).  The miRNA repress translation 
and direct degradation of their mRNA. The small size of the seed means that a 
single miRNA can regulate many, even hundreds of different genes. 
Several miRNAs have been identified as being biologically significant. 
miRNA have been linked to roles in differentiation and development. 
Expression of miR-181b in hematopoietic stem cells initiates differentiation into 
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the B-cell lineage (Chen et al., 2004). miR-375 has been shown to decrease 
insulin secretion in pancreatic β cells (Poy et al., 2004). Several miRNAs have 
been shown to act as tumor suppressors and oncogenes (sometimes called 
an onco-miRNA). Clear examples of tumor suppressor miRNAs are miR-15a 
and miR-16-1. Deletion of miR-15a and miR-16-1 increased the levels of the 
anti-apoptotic protein BCL2 in B cells resulting in a dysregulation of negative 
selection of B cells via apoptosis (Cimmino et al., 2005).  
Some miRNAs are targets of important cellular transcription factors, 
indicating significant co-evolution between these two classes of regulatory 
molecules. For example, the transcription factor forkhead box P3 (FOXP3), 
which is involved in the development and function of T regulatory cells, can 
upregulate the expression of miR-155 (Lodish et al., 2008). Finally, it was 
recently shown in our lab and in other labs, that the transcription factor p53 is 
able to upregulate the miR-34 family expression in response to DNA stress 
and damage (Corney et al., 2007). The miR-34 family is predicted to repress 
genes that promote the cell cycle. As a consequence, an increase in miR-34 
expression correlates to increased senescence and apoptosis (He et al., 
2007).  It has also been shown that miR-34 inhibits CD44+/CD133+ pancreatic 
cancer stem cell self-renewal in vitro and tumor-initiation in vivo (Ji et al., 
2009). Michael Clark’s group recently found that three clusters, miR-200c-141, 
miR-200b-200a-429, and miR-183-96-182 were downregulated in human 
breast cancer stem cells, normal human and murine mammary 
stem/progenitor cells, and embryonal carcinoma cells. miR-200c strongly 
suppressed the ability of normal mammary stem cells to form mammary ducts 
and tumor formation driven by human breast CSC in vivo (Shimono et al., 
2009). 
 17 
Given the important role of miRNAs, it is worth to further find the novel 
miRNAs that are important for cancer formation, and CSC self-renewal and 
differentiation.  Mouse model of mammary carcinoma will certainly accelerate 
the discovery of such miRNAs.  
 
1.7 Mouse model of mammary carcinoma   
The biology of the mouse mammary gland has been studied for many 
years. The normal development, lactation related changes and spontaneous 
tumors in the mouse mammary gland are well characterized. Better models of 
xenotransplantation that employs a humanized mouse may alleviate some 
pitfalls. For example, in some xenotransplantation models, human cytokines 
are exogenously administered or human stromal cells are co-injected to 
provide the transplanted CSC with a more native growth environment 
(reviewed in Pearson and Sanchez Alvarado, 2008). However, the complete 
understanding of cancer pathogenesis, particularly its earliest stages, is 
impossible without accurate autochthonous immunocompetent mouse models 
of human cancer. Recent advances in genetic engineering and genomics have 
provided the necessary tools to generate genetically defined mouse models 
which replicate such essential features of human cancers as molecular and 
histological characteristics, the process of cancer initiation and progression, 
and response to therapeutics (Table 1, reviewed in Frese and Tuveson, 2007; 
Jonkers and Berns, 2002; Van Dyke and Jacks, 2002). 
          The first generation of mouse models of breast cancer occurred 
between 1920 and 1960. Mammary tumors were induced by the treatment of 
certain genetic hormonal and environmental factors (e.g. mouse mammary 
tumor virus (MMTV), chemical carcinogens) to the mice (Allred and Medina, 
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2008; Borowsky, 2007). The second generation roughly starts from 1980 to 
1995, and is based on overexpression of specific oncogenes or deletion of 
specific tumor suppressor genes transgenic mice. Genes, including c-myc, 
p53, c-neu, SV40LT, TGFα, H-ras, cyclin D1, etc., have been studied, and 
over 100 mouse models have been generated (Allred and Medina, 2008; 
Borowsky, 2007; Cardiff et al., 2000). The third generation starts around 1997 
and includes conditional models prepared by activating or deleting specific 
genes in the mammary gland at a specific time. The commonly used 
promoters for mammary epithelium-specific gene expression are mouse 
mammary tumor virus long terminal repeat (MMTV-LTR), the whey acidic 
protein (WAP), and the beta-lactoglobin promoter (Allred and Medina, 2008; 
Borowsky, 2007).  
            Nevertheless, there are several important limitations in these models. 
For example, one limitation is that the promoters used in these models usually 
lead to gene mutation or overexpression in the majority of mammary epithelial 
cells, and this is in contrast to low frequency stochastic mutations in the 
human sporadic cancers. It would be ideal to have specific promoter target a 
low percentage of the specific cell population (stem cells, progenitors, 
differentiated cells). Furthermore, few of models accurately represent ER 
positive or progesterone receptor dependent human breast cancer, which 
account for over 70% or 50% human breast cancer, respectively. In addition, 
because of insufficient tissue specificity of used promoters, mice often develop 
other types of tumors, for example lymphomas, in addition to mammary 
neoplasms. Thus the next generation of models allowing introduction of 
genetic alterations restricted to the mammary epithelium and occurring in 
stochastic manner is required. 
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1.8 Concluding remarks and project overview 
 Due to heterogeneity in morphology, genetic lesions, molecular profiles, 
cell surface markers, cell proliferation kinetics, and response to therapy, 
studies of pathogenesis of breast cancer have been challenging, thereby 
leading to insufficient development of advanced diagnostic and treatment 
approaches. Modeling human cancer of the mammary gland in mouse 
provides unique opportunities for studying the nature of the disease, as well as 
for testing new diagnostic tools, drugs, therapeutic approaches, and strategies 
for prevention and control.  
 In this study, I generated a mouse model of mammary cancer by Cre-
loxP-mediated conditional inactivation of p53 and Rb specifically in mammary 
epithelial cells. In chapter 2, the generation of a mouse mammary cancer will 
be described in detail. My studies demonstrated that p53 inactivation led to 
formation of estrogen receptor positive raloxifene-responsive mammary 
carcinomas with features of luminal subtype B. Rb deficiency was insufficient 
to initiate carcinogenesis but promoted genomic instability and growth rate of 
neoplasms associated with p53 inactivation. I identified critical role of cIAP1, 
cIAP2 and Yap co-expression in mammary carcinogenesis and provided an 
explanation for the lack of recurrent amplifications of cIAP1, cIAP2 and Yap1. 
 In chapter 3, I isolated and functionally proved the existence of CSC in 
our mouse model of mammary carcinoma associated with p53 and/or Rb 
deficiency using the mammary stem cell markers CD24 and CD49f. I 
demonstrated that CSC have less percentage of comet tail positive cell and 
lower expression of Mad2 than cancer non stem cells (CnSC), indicating that 
CSC may have more stable genome than CnSC. Accordingly, CSC have less 
DNA damage after γ irradiation as compared to CnSC. To test involvement of 
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the stem cell compartment in the initiation of mammary carcinogenesis I have 
isolated mammary stem cells (MRU; CD24medCD49fhigh), and their progeny 
(Ma-CFC, CD24highCD49flow). I found that loss of either p53 or Rb leads to an 
increase in the number and proliferation rate of Ma-CFC but not MRU. Both 
parameters are further increased in Ma-CFC pool deficient for both p53 and 
Rb. These results demonstrate that mammary progenitor cells may be the 
principle targets for malignant transformation, and indentify expansion of 
progenitor cell pool as a novel cooperative effect of p53 and Rb inactivation on 
carcinogenesis. 
 In chapter 4, I studied the role of miRNA in CSC. I identified that miR-
376b and miR-467b, the most downregulated in both CSC and Mammary 
Stem Cells (MaSC) as compared to CnSC and normal differentiated mammary 
epithelial cells. I demonstrated that cIAP1 and cIAP2 are direct targets of miR-
376b and miR-467b. Furthermore, I showed that miR-376b and miR-467b 
reconstitution, as well as cIAP1/2 siRNA-mediated knockdown decrease 
mammosphere formation. These studies indicate that miR-376b/ miR-467b - 
cIAP1/2 pathway is important for CSC self-renewal and may represent a new 
target for development of new therapeutic approaches.  
 Finally I summarized the studies and outline the future directions in 
chapter 5. 
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 CHAPTER 2 
 
RB INACTIVATION ACCELERATES NEOPLASTIC GROWTH AND 
SUBSTITUTES FOR RECURRENT AMPLIFICATION OF CIAP1, CIAP2 AND 
YAP1 IN SPORADIC MAMMARY CARCINOMA ASSOCIATED WITH P53 
DEFICIENCY* 
 
2.1 Abstract 
Genetically defined mouse models offer an important tool to identify 
critical secondary genetic alterations with relevance to human cancer 
pathogenesis. We used newly generated MMTV-Cre105Ayn mice to inactivate 
p53 and/or Rb strictly in the mammary epithelium and to determine recurrent 
genomic changes associated with deficiencies of these genes. p53 inactivation 
led to formation of estrogen receptor positive raloxifene-responsive mammary 
carcinomas with features of luminal subtype B. Rb deficiency was insufficient 
to initiate carcinogenesis but promoted genomic instability and growth rate of 
neoplasms associated with p53 inactivation. Genome-wide analysis of 
mammary carcinomas identified a recurrent amplification at chromosome band 
9A1, a locus orthologous to human 11q22, which contains protooncogenes 
cIAP1 (Birc2), cIAP2 (Birc3) and Yap1. Interestingly, this amplicon was 
preferentially detected in carcinomas carrying wild-type Rb. However, all three  
------------------------------------------------------------------------------------------------------- 
* Accepted for publication as Cheng L, et al., Rb inactivation accelerates 
neoplastic growth and substitutes for recurrent amplification of the Birc2, Birc3 
and Yap1 in sporadic mammary carcinoma associated with p53 deficiency. 
Oncogene, in press 
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genes were overexpressed in carcinomas with p53 and Rb inactivation, likely 
due to E2F-mediated transactivation, and cooperated in carcinogenesis 
according to gene knockdown experiments. These findings establish a model 
of luminal subtype B mammary carcinoma, identify a critical role of cIAP1, 
cIAP2 and Yap1 co-expression in mammary carcinogenesis and provide an 
explanation for the lack of recurrent amplifications of cIAP1, cIAP2 and Yap1 
in some tumors with frequent Rb-deficiency, such as mammary carcinoma.  
 
2.2 Introduction 
Breast cancer is the most commonly diagnosed malignancy and the 
second leading cause of cancer-related deaths among women in the US 
(Jemal et al., 2010). p53 and Rb and their pathways are frequently altered in 
breast cancer. p53 is a transcription factor that regulates genes critical for cell 
cycle, apoptosis, senescence, and DNA repair, thus preventing genomic 
instability (Meek, 2009; Riley et al., 2008). Mutation of p53 is the most 
common genetic abnormality found in human cancer, and occurs in 20-40% of 
sporadic breast carcinomas (Borresen-Dale, 2003). Furthermore, p53 is 
mutated in individuals with Li-Fraumeni syndrome, a heritable condition in 
which early-onset breast cancers are the most prevalent cancer types (Malkin, 
1994). According to gene expression profiling, p53 mutations are most 
frequently associated with basal-like/ER negative (82%), ERBB2/HER2 
overexpressing/ER negative (71%) and luminal/ER positive subtype B (40%) 
breast cancers (Sorlie et al., 2001) all of which have poor prognosis (Hu et al., 
2006; Sorlie et al., 2001).  
 Mice homozygous for the p53 null allele (p53-/-) develop lymphomas or 
sarcomas within first three months (Donehower et al., 1992; Jacks et al., 
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1994). Development of some mammary tumors has been observed in p53+/- 
mice, but only on the BALB/c background (Kuperwasser et al., 2000). With the 
development of Cre-loxP technology, spontaneous mammary carcinogenesis 
has been observed after inactivation of wild-type p53 by either its deletion (Lin 
et al., 2004; Liu et al., 2007) or expression of a dominant negative form 
carrying a p53.R270H point mutation (Wijnhoven et al., 2005). Unfortunately, 
the interpretation of experiments has been somewhat complicated by 
formation of lymphomas and/or other neoplasms due to expression of the Cre 
transgene in lymphocytes and other tissues.  
 Rb is essential for cell cycle control and exerts diverse effects on cell 
proliferation, survival and differentiation (Burkhart and Sage, 2008). More 
recently the role of Rb in control of genomic instability has been demonstrated 
in cell culture experiments and in a mouse model of liver neoplasia (Knudsen 
et al., 2006; Reed et al., 2009). The observation that Rb is inactivated in 20-
35% of human breast cancers, suggests that it has an important role in the 
pathogenesis of these neoplasms (Bosco et al., 2007; Scambia et al., 2006). 
Additionally, other defects in Rb pathway components, such as Cyclin D1 
overexpression, and p16INK4A loss are frequently observed in human breast 
cancer (Geradts and Wilson, 1996; Roy and Thompson, 2006). However, in 
serial transplantations of Rb mutant mammary anlagen no significant 
differences were found in outgrowth of Rb-deficient and wild-type epithelia 
(Robinson et al., 2001). At the same time, transgenic mice expressing cyclin 
D1 in the mammary gland, hence deprived of functional Rb family proteins 
(Rb, p107 and p130), develop mammary neoplasms (Wang et al., 1994). 
Accordingly, it has been reported that inactivation of the whole Rb family by 
T121m, a fragment of SV40 T antigen, also leads to mammary carcinogenesis 
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(Simin et al., 2004).  
 In agreement with the potential cooperation between p53 and Rb 
inactivation, p53 deficiency results in acceleration of mammary carcinogenesis 
in the T121m model (Simin et al., 2004) as well as in transgenic mice expressing 
SV40 large T antigen (Li et al., 2000) which inactivates both p53 and all 
proteins of Rb family. However, it remains unclear if selective inactivation of 
Rb has any effect on cancer initiation or progression.  
 To ensure mammary epithelium-restricted Cre expression, we have 
established a new FVB/N MMTV-Cre transgenic mouse line (MMTV-
Cre105Ayn) which does not express Cre in lymphocytes and other tissues. 
Using this line we demonstrate that conditional inactivation of p53 results in 
ER-positive mammary carcinomas which carry recurrent amplification of 
cellular inhibitor of apoptosis (cIAP)1, cIAP2 and Yap1. Rb inactivation alone 
is insufficient to initiate mammary carcinogenesis but promotes genetic 
instability and accelerates neoplastic growth. Interestingly, lack of Rb 
suppresses genomic amplification of cIAP1, cIAP2 and Yap1. However, 
expression levels of these genes remain elevated and their knockdown 
decreases tumorigenicity, thereby indicating critical importance of the cIAP1, 
cIAP2 and Yap1 in mammary carcinogenesis. 
  
2.3 Materials and methods 
 Generation of transgene. To generate the mouse mammary tumor 
virus-long terminal repeat (MMTV-LTR)-Cre-Methallothionein-I (MT-I) pA 
plasmid, a HindIII-XhoI DNA fragment containing the 1.48 kb MMTV-LTR from 
pMAM (Clontech, Palo Alto, CA, USA) and XhoI-EcoRI fragment containing 
the 3.7 kb Cre-MT-I from pBS185 (Invitrogen, Carlsbad, CA, USA) were 
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simultaneously cloned into HindIII-EcoRI restricted pBluescript. The 5.18 kb 
KpnI digested MMTV-Cre transgene was isolated with GELase (Epicentre 
Technologies, Madison, WI, USA) and injected into pronuclei of fertilized 
oocytes of superovulated FVB/N mice at a concentration of 2 ng/ml. 
Mouse breeding. Male MMTV-Cre transgenic mice were crossed with 
female p53floxP/floxP (p53L/L), RbfloxP/floxP (RbL/L) or p53floxP/floxPRbfloxP/floxP 
(p53L/LRbL/L) mice to achieve, respectively, inactivation of p53 or Rb alone or 
together in the mammary epithelium. The resulting MMTV-Cre, p53L/L, MMTV-
Cre, RbL/L and MMTV-Cre, p53L/L RbL/L mice, were designated as p53ME-/-, 
RbME-/-, and p53ME-/- RbME-/- , respectively. Reporter mice 
Gt(ROSA)26SorTM1sor (Chai et al., 2000) were obtained from the Jackson 
Laboratory (Bar Harbor, Maine, USA). Mice carrying conditional alleles for p53 
(floxed exon 2-10) and/or Rb (floxed exon 19) were described elsewhere 
(Jonkers et al., 2001; Marino et al., 2000). All mice were placed on FVB/N 
genetic background by at least 10 backcrosses and only nulliparous females 
were used. All mice were maintained identically, following recommendations of 
the Institutional Laboratory Animal Use and Care Committee.  
 Genotyping. p53L/L and RbL/L mice were identified as described 
(Flesken-Nikitin et al., 2003). MMTV-Cre transgenic mice have been identified 
by primers Cre5’ (5’ GGA CAT GTT CAG GGA TCG CCA GGC G 3’) and 
Cre3’ (5’ GCA TAA CCA GTG AAA CAG CAT TGC TG 3’). PCR amplification 
of Cre results in 296 bp DNA fragment. The PCR temperature profile was 
94oC for 30 seconds, 60oC for 1 minute, and 72oC for 2 minutes with extension 
of the last cycle for 10 minutes at 72oC.   
Pathological evaluation. Mice were euthanized when mammary 
tumors reached 1 cm in diameter, at 700 days of age or after becoming 
 39 
moribund. Animals were evaluated grossly during necropsy and subjected to 
the systematic pathological assessment as descried earlier (Flesken-Nikitin et 
al., 2003; Zhou et al., 2006; Zhou et al., 2007). All lesions were identified 
according to the Classification of Neoplasia of Genetically Engineered Mice 
(Cardiff et al., 2000) endorsed by the Mouse Models of Human Cancer 
Consortium (NIH/NCI). 
 Histochemical analyses. Immunohistochemical analysis of paraffin 
sections of paraformaldehyde-fixed tissue was done by a modified avidin-
biotin-peroxidase (ABC, Vector Laboratories, Burlingame, CA, USA) technique 
with antigen retrieval as described earlier (Zhou et al., 2006). Primary 
antibodies to the following antigens were used: cytokeratin 5 (CK5, Covance, 
Berkeley, CA, USA, 1:1000), CK6, (Covance, 1:300), CK8 (Developmental 
Studies Hybridoma Bank, University of Iowa, 1:50), Ki67 (Novocastra 
Laboratories, Bannockburn, IL, USA, 1:1000), smooth muscle actin (SMA, 
Spring Bioscience, Fermont, CA, USA, 1:300), ERα (Santa Cruz, Santa Cruz, 
CA, USA, 1:200), and progesterone receptor (PR; Santa Cruz, 1:200). 
Enzymatic detection of bacterial β-galactosidase was performed as previously 
described (Flesken-Nikitin et al., 2003; Zhou et al., 2007). All quantitative 
analyses were performed on digitally captured images as described in (Zhou 
et al., 2006).  
 Western blotting analyses. Proteins
 
were determined using Western 
blotting, as described previously (Matoso et al., 2008). Briefly, cells were 
rinsed twice on ice with ice-cold PBS, extracted in lysis buffer and total protein 
(30 µg) was separated on 6%-10% SDS-PAGE gels in Mini-Protean II cell 
(BioRad, Hercules, CA, USA). Following transfer to polyvinylidene difluoride 
membranes, proteins were blocked with 5% milk (w/v), 0.1% Tween 20 in TBS 
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for 1 hours, followed by exposure to the before exposure to the primary 
antibody to  ERα (1:200, Santa Cruz), PR (1:200, Santa Cruz), E2F1 (1:500, 
Cell Signaling, Danvers, MA, USA), E2F3 (1:200, Santa Cruz), Mad2 (1:200, 
Santa Cruz), Yap1 (1:300, Cell Signaling), cIAP1 (1:300, Abcam, Cambridge, 
MA, USA) and Gapdh (1:1000, Advanced immunochemical Inc, Long Beach, 
CA, USA) overnight at 4°C. After incubation with secondary horseradish 
peroxidase–conjugated antibody (Santa Cruz), the filters were incubated with 
SuperSignal® West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, 
USA). To normalize for differences in loading, the blots were stripped and 
reprobed with mouse anti-Gapdh monoclonal antibody. 
Cell culture. To prepare mammary epithelial cells, mammary glands 
were dissected from 3-6 months old females. The tissue was placed in 
EpiCult-B medium (StemCell Technologies, Vancouver, BC, Canada) with 5% 
fetal bovine serum (FBS, Sigma, St. Louis, MO, USA), 300 U/ml collagenase 
(StemCell Technologies) and 100U/ml hyaluronidase (StemCell Technologies) 
for 8 hours at 37oC. The dissociated tissue fragments were resuspended in 
0.64% NH4Cl for lysis of the red blood cells. The further dissociation of 
fragments was obtained by their gentle pipetting in 0.25% Trypsin (Cellgro, 
Manassas, VA, USA) for 2 min, followed by placing into 5 mg/ml dispase 
(StemCell Technologies) and 0.1 mg/ml DNase (StemCell Technologies) for 3 
min and filtration through a 40-µm mesh. Derivation of MCN1, MCN2, MCN3 
and MCN9 cells is described in Table 2.3. Cells were cultured in HAM’s 
medium DMEM/F12, 50/50 Mix; Cellgro), supplemented with 5% fetal bovine 
serum, 2 mM L-Glutamine, 1 mM Na-Pyruvate, 5  µg/ml Insulin. MCF7 (ATCC, 
Manassas, VA), a human breast cancer cell line, was cultured in DMEM 
containing 10% fetal bovine serum and 10 µg/ml Insulin. All cell lines were 
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maintained in 5% CO2 atmosphere at 37°C. 
 Mammary fat pad transplantation, raloxifene and siRNA treatment.  
The number 4 pair of mammary glands of anaesthetized, 3-week-old female 
FVB mice were surgically exposed under sterile condition. 106 tumor cells in 
100 µl sterile PBS were injected into the cleared fat pad using a Hamilton 
syringe and 25 gauge needle and tumor formation was monitored daily. 
Tumors were measured in three dimensions with a caliper, and the volume 
was calculated using the formula: V = π/ 6 (L x W x H). Raloxifene (10 µg/g 
body weight in DMSO) was applied s.c. to mice every two days from second 
day after cell transplantation. For siRNA treatment, 100 µl 5 µM siRNA was 
mixed with 100 µl atelocollagen (AteloGene™ Systemic Use; Koken, Tokyo, 
Japan) and administered locally as described (Minakuchi et al., 2004). All mice 
were monitored daily and the experiments were terminated after tumors 
reached volume 0.8 cm3. 
 Proliferation and apoptosis assays. One day before the raloxifene 
(Sigma) or cIAP1, cIAP2, and Yap1 siRNAs (Dharmacon, Lafayette, CO, USA) 
treatment, tumor cells were passaged to 12-well culture plates. Next day, after 
tumor cells reached around 80% confluence, they were treated with raloxifene 
in DMSO or 100 nM of siRNAs for 24 hours in 5% CO2 at 37°C. After 24 
hours, tumor cells were incubated with 3 µg/ml bromodeoxyuridine (BrdU, 
Sigma) for 2 hours at 37°C, and BrdU was detected by staining with anti-BrdU
 
antibody (1:50, Becton Dickinson, Franklin Lakes, NJ, USA) as described 
previously (Nikitin and Lee, 1996). Apoptosis was detected by staining of cells 
with anti-cleaved Caspase 3 antibody (Cell Signaling, 1:200). All quantitative 
analyses were performed on digitally captured images as described in (Zhou 
et al., 2006). For estimation of proliferating and apoptotic cells, 10 images with 
 42 
area 10,384 µm2 each were analyzed in each sample. Approximately 2,000 
cells were analyzed in a single experiment. Experiments were performed in 
triplicate. 
Comparative genomic hybridization assay. Genomic DNA of 
mammary tumors from p53ME-/- and p53ME–/–; RbME–/– mice was assayed by 
comparative genomic hybridization. Genomic DNA from FVB female mice was 
used as a control. Genomic DNA was extracted using DNeasy Tissue Kit 
(Qiagen, Valencia, CA, USA). Mouse BAC genomic arrays, each composed of 
6500 RPCI-23 or PRCI-24 clones, were prepared in the Roswell Park Cancer 
Institute Microarray Core Facility (Buffalo, NY, USA). Data were analyzed as 
previously described (Zhou et al., 2006).  
Spectral karyotyping (SKY). Metaphase chromosomes for SKY were 
prepared after exposure of the tumor cells (passages 2-6) to colcemid (Roche, 
Indianapolis, IN) for 1–3 hours at a final concentration of 0.1 µg/ml. The cells 
were lysed in hypotonic solution (0.075 M KCl), and the nuclei were fixed in 
methanol and acetic acid (3:1). SKY was performed as described by Liyanage 
et al. (Liyanage et al., 1996). For protocol details, please refer to Padilla-Nash 
et al. (Padilla-Nash et al., 2007). Differentially labeled chromosome-specific 
painting probes were hybridized simultaneously onto metaphase 
chromosomes. Images were acquired with a custom-designed triple-pass filter 
using the SpectraCube SD200 (Applied Spectral Imaging, Vista, CA, USA) 
connected to an epifluorescence microscope (DMRXA, Leica Microsystems, 
Wetzlar, Germany). At least 10 metaphases and corresponding inverted 4,6-
diamidino 2-phenyl-indole (DAPI) images were analyzed for each tumor, and 
karyotypes were defined using the nomenclature rules from the International 
Committee on Standardized Genetic Nomenclature for Mice (Davisson, 1994). 
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Neutral comet and centrosome assays. Cells were processed for 
comet tail formation using neutral comet assay condition according to the 
manufacturer’s instructions (Trevigen, Gaithersburg, MD, USA). Briefly, cells 
were mixed with LMAgarose at a ratio of 1:10 (v/v) and then plated onto 
CometSlides at 4°C in the dark for 10 min. Slides were immersed in prechilled 
lysis solution at 4°C for 30 min, and then transferred to a horizontal 
electrophoresis apparatus at 20V for 10 min. Finally, slides were stained with 
SYBR Green I, and imaged by fluorescence microscopy. Centrosomes were 
detected with mouse monoclonal γ-tubulin antibody (1:5000, Sigma), followed 
by FITC-conjugated anti-mouse secondary antibodies (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) and DAPI (10 µg/ml 
Sigma) nuclear counterstaining.  
AdCre, E2F1 knockdown and doxorubicin treatment assays. Cells 
were treated with AdCre or blank adenovirus (6x107 pfu/ml at MOI 200, the 
University of Iowa Gene Transfer Vector Core, Iowa City, IA, USA) for 2 hours 
in 5% CO2 atmosphere at 37°C and cultured for a further 48 hours and 
processed for mRNA isolation. In order to knockdown E2F1, cells were 
transfected with E2F1 siRNAs (Dharmacon) for 24 hours in 5% CO2 at 37°C 
and then processed for mRNA isolation. For doxorubicin treatment assay, cells 
were treated with 2 µg/ml doxorubicin for 12 hours, followed by RNA isolation 
and analysis. 
 Real-time PCR and RT-PCR. Quantitative PCR analysis was carried 
out on an ABI 7500 HT Real-time PCR System (Applied Biosystems, Foster 
City, CA, USA). The primers for quantification of gene copy number are 
described in (Zender et al., 2006). Quantification of mRNA expression of 
cIAP1, cIAP2, Yap1, E2F1 and Mad2 was performed using TaqMan probes 
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(Applied Biosystems). Samples were normalized to the level of Gapdh. 
 Statistical Analyses. All statistical analyses in this study were done 
using InStat 3.06 and Prism 5.01 software (GraphPad, Inc., San Diego, CA, 
USA) as described previously (Zhou et al., 2006). 
 
2.4 Results 
Generation of MMTV-Cre transgenic mice. To avoid genetic 
background variations and frequent lymphomas due to Cre expression in 
lymphocytes and other tissues we generated mice expressing Cre under the 
control of MMTV-LTR (Fig 2.1A) and screened founders for exclusive 
expression of Cre in the mammary epithelium after their crosses with 
Gt(ROSA)26SorTM1sor reporter mice. One out of five tested lines, FVB/N 
Tg(MMTV-Cre)105Ayn expressed Cre selectively in the mammary epithelium 
(Table 2.1 and Fig 2.2) Furthermore, no lymphomas or other non-mammary 
neoplasms were observed in crosses of this line with p53floxP/floxP mice. 
Therefore, it has been chosen for all subsequent experiments and will be 
described as MMTV-Cre. 
 Inactivation of p53 in mammary epithelium leads to neoplastic 
lesions and Rb loss accelerates carcinogenesis. Conditional inactivation of 
p53 was sufficient for mammary carcinogenesis in our model. Eight out of 16 
(50%) p53
ME-/-
 mice (see Materials and Methods for abbreviations) and none 
out of eight (0%) RbME-/- mice developed mammary neoplasms by 700 days of 
age (Fig 2.1B). Fifteen out of 17 (88%) p53ME-/- RbME-/- mice developed 
mammary neoplasms. All neoplasms arising in p53ME-/- and p53ME-/- RbME-/- 
mice have lost both copies of p53 and p53 and Rb, respectively (Fig 2.3). The 
median tumor-free survival of p53ME-/- RbME-/- mice was significantly shorter  
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Figure 2.1 Generation and characterization of a mouse model of 
mammary carcinoma associated with p53 and Rb deficiency.   
A, Generation and characterization of MMTV-Cre transgenic mice. (Top) The 
MMTV-Cre transgene consists of the 1.48 kb MMTV-LTR promoter followed 
by the 1.1 kb Cre gene and the 1.2 kb MT-1 polyadenylation site. (Bottom) 
Identification of MMTV-Cre transgenic mice by PCR genotyping. 296 bp and 
194 bp fragments are diagnostic for the Cre gene and mouse Rb gene, 
respectively. MMTV-Cre founder mice are identified in lanes 1, 4, 5, 7, and 8 
(lines MMTV-Cre104Ayn, 105Ayn, 106Ayn, 107Ayn, 108Ayn, respectively). B, 
Survival of mice with mammary-specific inactivation of p53 (n=16, median 669 
days), Rb alone (n=8, median 700 days) or p53 and Rb together (n=17, 
median 504 days). P for log-rank comparisons of survival curves of p53ME-/- 
and p53ME-/-RbME-/- mice is 0.0058. C, Neoplasms of the mammary epithelium 
in p53ME-/- and p53ME-/-RbME-/- mice. (Top) Mammary carcinomas with mainly 
(Left) solid pattern of growth (arrow) and dense fibrous stroma (arrowhead), 
(Middle) glandular pattern (arrow), (Right) spindle cell pattern with diverse cell 
types (arrow). H&E stain. (Middle) Lung metastasis of mammary carcinoma 
(arrow) (Left), H&E stain. Expression of CK8, CK5 and smooth muscle actin 
(SMA) in carcinoma cells (arrows) (Middle and Right). (Bottom) Expression of 
Mad2, ER and PR in carcinoma cells (arrows). ABC Elite method, hematoxylin 
counterstaining. Calibration bar for all images: 100 µm. 
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Table 2.1 Characterization of Cre activity in 5 MMTV-Cre mouse lines*. 
 
Lines 
104A 105 106 107 108 
Tissues 
Lung 0** 0 0 0 <0.1 
Liver 0 0 0 0 0 
Spleen <0.1 <0.1 0 0 5-10 
Nulliparous mammary 
gland  
<1 1 0 0 5 
Multiparous mammary 
gland  
NA*** 30-60 NA NA 30-50 
* MMTV-Cre mice were crossed to Gt(ROSA)26SorTM1sor reporter mice.  
** % of positive cells was determined by counting of at least 300 cells in 5 
random fields of view (9 x 103 µm2 area each).  
*** NA, not available. 
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Figure 2.2 Cre expression in the mammary glands of Tg(MMTV-Cre), 
Gt(ROSA)26SorTM1sor mice.  
Only mammary epithelial cells contain β-galactosidase (arrow, green color). 
No Cre expression is detected in lymphocytes of the inguinal lymph node (left, 
arrowhead). Counterstaining with nuclear fast red. Calibration bar: (Left) 200 
µm, (Right) 30 µm. 
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Figure 2.3 PCR analysis of p53 and Rb gene structures in mammary 
carcinoma (p53ME-/- and p53ME-/-RbME-/- lanes) and normal cells (p53L/L and 
p5 L/LRbL/L lanes).  
Cells were isolated from dissociated tissues by magnetic purification with 
CD31 (endothelial cell), CD45 (hematopoietic cells), Ter119 (hematopoietic 
cells), and CD140a (stromal cells) antibodies using CELLection Biotin Binder 
Kit (Invitrogen). 198-bp and 316-bp fragments are diagnostic for the excised 
and floxed alleles of the p53 gene, respectively. 269-bp and 295-bp fragments 
are diagnostic for the excised and floxed alleles of the Rb gene, respectively.  
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than that of p53ME-/- mice (P=0.0058). Thus, although Rb inactivation alone is 
insufficient for initiation of mammary carcinogenesis, p53 and Rb cooperate in 
suppression of carcinogenesis.  
 In agreement with the low frequency (1% of cells) of Cre expression in 
the mammary glands, the majority of mice developed only one mammary 
tumor (Table 2.2). Eleven (3 out of 27) and 10 (4 out of 40) percent of p53ME-/- 
and p53ME-/- RbME-/- mice, respectively developed lung metastasis. Eight out of 
27 (30%) and 10 out of 43 (23%) neoplasms in p53ME-/- and p53ME-/- RbME-/-  
 trabecular patterns and were separated by desmoplastic stroma. One tumor 
in each group was an adenosquamous carcinoma. The remaining tumors were 
poorly differentiated carcinomas and consisted of CK8 positive epithelioid, 
spindle or polygonal, frequently pleomorphic, cells. The degree of 
pleomorphism was particularly notable in two out of 18 (11%) and nine out of 
32 (28%) neoplasms from p53ME-/- and p53ME-/- RbME-/- mice respectively. The 
frequency of poorly differentiated carcinomas of p53ME-/- RbME-/- mice was also 
somewhat higher than that of p53ME-/- mice (67% vs. 75%). However, both 
parameters were not statistically significant (Fisher's exact test two-sided 
P=0.2866 and 0.579, respectively). Seven out of 32 poorly differentiated 
neoplasms of p53ME-/- RbME-/- mice but none out of 18 those of p53ME-/- mice 
contained significant (over 5%) areas of solid or glandular differentiation 
(Fisher's exact test two-sided P=0.04). SMA, CK5 or CK6 positive cells were 
present in one third of neoplasms but did not exceed 3-5% of tumor cells. As 
expected from the loss of Rb function, neoplastic cells deficient for both p53 
and Rb proliferated significantly faster than cells with p53 deficiency alone in 
histologically comparable areas (Fig. 2.4). In agreement with mice, 
respectively, were relatively well differentiated carcinomas (Fig 2.1C and Table  
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          Table 2.2 Neoplasms in p53ME-/- and p53ME-/- RbME-/- mice. 
 
Genotype p53ME-/- p53ME-/- RbME-/- 
No of tumors per tumor bearing mouse 1.12 (27/24)* 1.13 (43/42) 
Well differentiated carcinoma, % 30 (8/27) 23 (10/43) 
Poorly differentiated carcinoma, % 67 (18/27) 75 (32/43) 
Adenosquamous carcinoma, % 3 (1/27) 2 (1/43) 
Lung metastasis, % 11 (3/27) 10 (4/43) 
* Numbers in parentheses indicate number of mice with neoplasm out of total 
number of tumor bearing mice. 
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Figure 2.4 Cell proliferation in mammary carcinomas of p53ME-/- and 
p53ME-/- RbME-/- mice. 
(Top) immunohistochemical detection of Ki67 (arrows). Counterstaining with 
hematoxylin. Calibration bar, 50 µm. (Bottom) Quantitative analysis of Ki67 
immunostaining demonstrates that neoplastic cells in mammary carcinomas 
associated with p53 and Rb deficiency proliferate faster as compared to 
mammary carcinoma cells with p53 deficiency alone (Mean ± SD, 32.58 ± 8.8 
vs 20.67 ± 8.15, ten tumors of comparable histological types per each group, 
P=0.0023).  
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2.2). In these tumors neoplastic cells formed solid, glandular and preferentially 
luminal differentiation of the neoplasms, all of them (10 out of 10 in each 
group) expressed ERα in at least 25% of cells (Fig 2.1C). All tumors also 
expressed a downstream target of ERα, PR. At the same time, as 
characteristic for luminal subtype B carcinomas (Hu et al., 2006), all tumors 
expressed mitotic checkpoint protein Mad2. 
 Mammary neoplasms respond to hormone therapy with a selective 
estrogen receptor modulator. In addition to detection of ER and PR in all 
mammary carcinomas by immunohistochemical analysis (Fig 2.1C), we 
confirmed their expression in the cell lines MCN1, MCN2 and MCN3 
established from those tumors (Fig 2.5A and Table 2.3). To determine if 
tumors respond to hormone therapy, effects of raloxifene, a selective estrogen 
receptor modulator (SERM), which competes with endogenous estrogen for 
ERα binding (Sporn et al., 2004), were tested in all three mammary carcinoma 
cell lines. According to the BrdU incorporation assay, raloxifene treatment 
resulted in a dose dependent cell proliferation decrease in all three cell lines 
within concentration range from 10 nM to 1 µM (P<0.05 in all treatments and 
cell lines, Fig 2.5B). Raloxifene also significantly delayed the neoplastic growth 
after mammary fat pad transplantation of MCN1 (P=0.0132) and MCN2 
(P=0.0088; Fig 2.5C). Taken together, these results confirm functional status 
of ERα in p53ME-/- and p53ME-/- RbME-/-mouse models of mammary carcinoma. 
 Rb inactivation affects the pattern of secondary genetic alterations 
and increases genomic instability of mammary cancer associated with 
p53 deficiency. To determine whether there were any specific genetic 
aberrations associated with mammary carcinomas in our models, comparative 
genomic hybridization array (aCGH) analyses were performed on DNA  
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Figure 2.5 Mammary neoplasms respond to hormone therapy with 
raloxifene.  
A, Western blot of ERα, and PR in MCN1, MCN2, MCN3 and MCF7 cell lines. 
To normalize for differences in loading, the blots were stripped and reprobed 
with mouse anti-Gapdh monoclonal antibody. B, Effects of raloxifene on 
proliferation of mammary carcinoma cells as determined by BrdU incorporation 
and compared to control (Mean ± SD, n=3 in each group, P < 0.05, indicated 
as *). All MCN cell lines are p53 null and have either two (+/+) or no (-/-) 
functional copies of the Rb gene. C, Effects of raloxifene on tumor growth in 
vivo. MCN1 and MCN2 cells (106) were transplanted to cleared fad pad of 4 
weeks old FVB mice. According to the tumor volume measurements 12 days 
after transplantation, raloxifene (raloxifene +) significantly delays the tumor 
growth of MCN1 (P=0.0132) and MCN2 (P=0.0088) cells as compared to 
control group without raloxifene treatment (raloxifene -).  
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                            Table 2.3 Mammary carcinoma cell lines. 
 
Cell line 
Mouse 
genotype 
Mouse age 
(days)  
Tumor type 
p53/Rb 
status 
MCN1 p53ME-/- 473 
Poorly differentiated 
carcinoma 
p53-/-Rb+/+ 
MCN2 p53ME-/- RbME-/- 506 
Poorly differentiated 
carcinoma 
p53-/-Rb-/- 
MCN3 p53ME-/- 434 Solid carcinoma p53-/-Rb+/+ 
MCN9  p53ME-/- RbME-/- 508 Solid carcinoma p53-/-Rb-/- 
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Figure 2.6. Genomic alterations in mammary carcinomas of p53ME-/- and 
p53ME-/- RbME-/- mice.  
A, The log2 ratios for each chromosome in order from 1p to Xqter. (Top) 
Chromosomal regions with consistent gene copy number alterations (5 out of 
6 samples, arrows). Carcinomas of p53ME-/- mice: significant gain and loss are 
mapped to the chromosomal bands 9A1 and 12C2 - 12F1, respectively. 
Carcinomas of p53ME-/- RbME-/- mice:  significant gain at 6A1 and 6A2. B, 
Spectral Karyotyping analysis of chromosome metaphase spreads of primary 
tumor cells (Top, p53ME-/-; Bottom, p53ME-/- RbME-/-). Karyotype of metaphase 
spread with classification pseudo-color and its corresponding inverted-DAPI. 
Arrow, net gain of chromosome 9A1 in tumors of p53ME-/- mice. C, (Left) 
Comparison of aCGH profiles of tumors from p53ME-/- and p53ME-/- RbME-/- mice. 
(Right) Chi-square test of the number of BAC in altered chromosome region of 
tumors from p53ME-/- and p53ME-/- RbME-/- mice. 
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isolated from these neoplasms (Fig 2.6). The genome of p53 deficient tumors 
was characterized by a recurrent amplification (5 out of 6 tumors) at 
chromosomal band 9A1. Additionally, chromosome bands 12C2 - 12F1 were 
deleted in 5 out of 6 mammary tumors from p53ME-/- mice. Interestingly, in 
mammary tumors from p53ME-/- RbME-/- mice (Fig 2.6 A), only 1 out of 6 tumors 
had a genomic amplification of 9A1 and none carried the deletion at 12C2 -
12F1. At the same time, 5 out of 6 (83%) mammary tumors from p53ME-/-RbME-
/-
 mice had amplification at chromosome 6A1 and 6A2, while only 2 out of 6 
(33%) mammary tumors from p53ME-/- mice had amplification of these regions. 
Analysis by SKY showed chromosomal aberrations that resulted in a net gain 
of chromosome 9A1 (Fig 2.6B). 
 aCGH data also demonstrated that neoplasms from p53ME-/- RbME-/- 
mice contained 20% more genomic imbalances compared to those in p53ME-/- 
mice (Fig 2.6C). Consistently, SKY analysis demonstrated a high degree of 
aneuploidy and an increased rate of structural chromosomal instability 
(P=0.0213) in carcinomas from p53ME-/- RbME-/- mice. This was measured as 
the presence of de novo non-clonal chromosome aberrations per cell (Fig 2.6B 
and Table 2.4). 
 Previous studies demonstrated that E2F family, one of the main Rb 
downstream effectors, mediates DNA double strand break accumulation and 
contribute to mitotic defects and genomic instability (Pickering and Kowalik, 
2006) at least in part by activating Mad2 expression (Hernando et al., 2004). 
Consistently with those observations, higher levels of E2F1, E2F3 and Mad 2 
were found in primary tumors from p53ME-/- RbME-/- mice as compared to p53ME-
/- mice (Fig 2.7A). Accordingly, tumor cells deficient for both p53 and Rb 
contained higher subpopulation with multiple centrosomes (Fig 2.7B) and  
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                                                           Table 2.4 Summary of SKY analysis. 
 
Genotype 
Modal 
number 
Ploidy 
Metaphases 
analyzed 
# of 
metaphase
s w/ modal 
number 
Clonal 
aberrations 
Non-clonal 
aberrations 
Rate of 
structural 
instability 
p53-/- 74 4n- 10 3 3 7 0.7 
p53-/- 100 5n 10 3 6 6 0.6 
p53-/- 71 4n- 10 3 10 8 0.8 
p53-/-Rb-/- 84 4n+ 10 2 2 12 1.2 
p53-/-Rb-/- 71 4n- 10 5 9 11 1.1 
p53-/-Rb-/- 68 3n+ 6 2 5 10 1.6 
 
 
  
 
6
0
 
 61 
 
 
 
Figure 2.7 Rb inactivation promotes genomic instability. 
A, (Left) Western blot of E2F1, E2F3, and Mad2 in primary tumor cells from 
p53ME-/- and p53ME-/- RbME-/- mice. (Right) Relative Mad2 mRNA expression in 
carcinomas of p53ME-/- and p53ME-/- RbME-/- mice (Mean ± SD, 2.9 ± 2.1 versus 
6.3 ± 4.0, n=10, P = 0.0411, indicated as *). B, (Top) Immunofluorescence 
staining (γ-tubulin) of centrosomes in primary tumor cells from p53ME-/- and 
p53ME-/- RbME-/- mice. (Bottom Left) Percentage of cells with more than 2 
centrosomes is higher  in cells from p53ME-/- RbME-/- mice, as compared to that 
in cells from p53ME-/- mice (75.8 ± 9.0 versus 49.6 ± 12.0, n=10, P = 0.0083). 
(Bottom Right) Tumor cells from p53ME-/- RbME-/- mice have higher average 
number of centrosomes per cell than that from p53ME-/- mice (4.96 ± 0.76 
versus 3.34 ± 0.90, n=10, P=0.0152,). C, (Left) Representative images of 
neutral comet assay with primary tumor cells from p53ME-/- and p53ME-/- RbME-/- 
mice. (Right) Tumor cells from p53ME-/- RbME-/- mice have higher percentage of 
cells with comet tail as compared to p53ME-/- (18.9 ± 1.3 versus 11.5 ± 3.3, 
n=10, P = 0.0232). 
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double strand breaks (Fig 2.7C) according to γ-tubulin staining and neutral 
comet assays, respectively. 
 
cIAP1, cIAP2 and Yap1 are regulated by E2F and cooperate in mammary 
carcinogenesis. The chromosome band 9A1 is orthologous to human 
chromosome band 11q22, which is frequently amplified in human cancers 
(Overholtzer et al., 2006) and contains the protooncogenes cIAP1 (Birc2), 
cIAP2 (Birc3) and Yap1. Given the potential importance of these genes for 
human cancer we fine mapped the extent of the amplicon by demonstrating 
lack of amplification of the flanking genes Tmem123 (Porimin) and Pgr (PR) 
genes by quantitative real time PCR (qPCR) in tumors from p53ME-/- mice (Fig 
2.8A). At the same time, qPCR was also used to confirm the aCGH results 
indicating lack of recurrent amplification of cIAP1, cIAP2 and Yap1 in 
carcinomas of p53ME-/- RbME-/- mice. 
 Notably, mRNA expression analyses demonstrated that all three genes 
were similarly overexpressed in carcinomas of both p53ME-/- and p53ME-/- RbME-
/- mice (Fig 2.8B). Since promoter regions of all three genes contain E2F 
binding sites (Fig 2.9), E2F regulation of cIAP1, cIAP2 and Yap1 expression 
was tested by E2F1 knockdown. Consistent with the Rb/E2F regulation model, 
knockdown of E2F1 by siRNA in mammary carcinoma cell lines resulted in 
significant (P<0.05) downregulation of cIAP1, cIAP2 and Yap1 24 hours after 
transfection (Fig 2.8C). Cre-loxP-mediated inactivation of Rb alone or together 
with p53 in primary mammary epithelial cells resulted in increased expression 
of cIAP1 and cIAP2 at 24 hours followed by further increase at 72 hours (Fig 
2.8C). Inactivation of p53 alone had only marginal effect on expression of 
cIAP1 and led to decreased expression of cIAP2. Furthermore, induction of  
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Figure 2.8 Copy number and expression of cIAP1, cIAP2 and Yap1 in 
mammary carcinomas of p53ME-/- and p53ME-/- RbME-/- mice.  
A, (Top) The map of the genes in the chromosome 9A1 region under study. 
(Bottom) Mammary carcinomas from p53ME-/- mice have higher cIAP1, cIAP2 
and Yap1 gene copy number than those from p53ME-/- RbME-/- mice (Mean±SD, 
n=10 in each group). cIAP1: 17.6±19.2 versus 3.1±3.1; cIAP2: 20.3±19.7 
versus 3.1±2.4 and Yap1: 19.03±17.96 versus 4.08±2.95, respectively. * 
indicates P<0.05. DNA copy number of Tmem123 and Pgr is similar between 
the cells from these two different types of mice (Tmem123: 1.88±1.36 versus 
1.78±1.41 and Pgr: 1.87±1.6 versus 1.72±1.32). B, (Left) Overexpression of 
cIAP1, cIAP2 and Yap1 in mammary carcinomas from both p53ME-/- and 
p53ME-/-RbME-/- mice as compared to the wild-type (WT) mammary epithelium 
(Mean±SD, n=10 in each group) cIAP1: 7.80±8.61 (p53ME-/-), 12.30±15.30 
(p53ME-/- RbME-/-) versus 1.05±0.13 (WT); cIAP2: 6.31±10.89 (p53ME-/-), 
5.73±6.72 (p53ME-/- RbME-/-) versus 1.06±0.18 (WT), and Yap1: 18.29±27.12 
(p53ME-/-), 19.12±20.15 (p53ME-/- RbME-/-) versus 1.16±0.19 (WT), * indicates 
P<0.05. (Right) Western blot of cIAP1 and Yap1 in MCN1, MCN2, MCN3 cells 
and primary culture of wild type mammary epithelium (WT). C, Expression of 
E2F1, cIAP1, cIAP2, and Yap1 after E2F1 knockdown by E2F1 siRNA as 
compared to scrambled siRNA control (Mean±SD, n=4 in each group; P<0.05 
is indicated as*). All MCN cell lines are p53 null and have either two(+/+) or 
no(-/-) functional copies of the Rb gene (Top Left). Relative expression 
(Mean±SD, n=4 in each group) of cIAP1 (Top Right), cIAP2 (Bottom Left) and 
Yap1 (Bottom Right) collected at 24 and 72 hours after treatment of mammary 
epithelium cells from floxed p53 (p53L/L), Rb (RbL/L), or p53L/LRbL/L mice with 
blank Adenovirus (Blank) or AdCre (P<0.05 is indicated as *). 
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p53 expression by treatment with doxorubicin did not result in decreased 
expression of cIAP1 and cIAP2 as compared to p53 deficient cells (Fig 2.10). 
Yap1 expression also increased after Rb inactivation but lacked significant 
increase immediately after simultaneous inactivation of p53 and Rb genes. 
Computational analysis of the Yap1 gene identified a putative p53 binding site 
in the intron 1 (Fig 2.9). Consistently, decrease and increase of Yap1 
expression was observed after deletion and doxorubicin-induced upregulation 
of p53, respectively (Fig 2.8C and Fig 2.10C). Taken together, these 
observations indicate that defective Rb/E2F pathway was likely to be sufficient 
for immediate upregulation of cIAP1 and cIAP2, as well as later 
overexpression of Yap1, thereby avoiding the need for genomic amplification 
of these genes during mammary carcinogenesis. 
 To further elucidate the roles of cIAP1, cIAP2 and Yap1 in mammary 
carcinomas we used siRNA to knockdown the expression of these genes (Fig 
2.11 and Fig 2.12). Downregulation of each gene individually resulted in 
significant decrease in cell proliferation and increase in apoptosis (Fig 2.11A). 
The effect was even more pronounced after two or all three genes were 
inactivated simultaneously. To test tumorigenic properties of cIAP1, cIAP2 and 
Yap1, respective siRNAs were delivered with atelocollagen to mammary 
carcinoma cells transplanted to the mammary fat pad. Downregulation of each 
gene, individually, resulted in deceleration of tumor growth. Similarly to cell 
culture results, suppression of tumor growth was most pronounced by 
simultaneous downregulation of 2 and particularly all 3 genes. Taken together, 
these observations demonstrate that cIAP1, cIAP2, and Yap1 are important for 
mammary carcinogenesis associated with p53 deficiency and cooperate to 
promote neoplastic growth.  
 67 
 
Figure 2.9 Analysis of cIAP1, cIAP2, and Yap1 genes for binding sites.  
Promoter regions of cIAP1, cIAP2, and Yap1 contain E2F binding sites 
according to TFSEARCH: Searching Transcription Factor Binding Sites 
(version 1.3), UCSC Genome Browser 
(http://molsun1.cbrc.aist.go.jp/research/db/TFSEARCH.html). Yap1 gene 
contains p53 binding site in the intron 1 according to the Program p53MH 
(http://linkage.rockefeller.edu/ott/p53MH.htm). 
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Figure 2.10 Effect of doxorubicin on cIAP1, cIAP2 and Yap1 expression.   
Primary mammary epithelium cells from either p53 floxed (p53L/L) or wild-type 
mouse were exposed to AdCre for 48 hrs followed by treatment with 
doxorubicin (Dox, 2 µg/ml) for 12 hours (Mean ± SD, n=4 in each group, 
P<0.05, as compared to control, is indicated as*). 
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Figure 2.11 cIAP1, cIAP2, and Yap1 cooperate in mammary 
carcinogenesis.  
A, Downregulation of either cIAP1, cIAP2 or Yap1 by siRNA in primary 
mammary carcinoma cells leads to decreased cell proliferation (left) and 
increase of apoptosis (right) as compared to scrambled siRNA control. Both 
effects are more pronounced after inactivation of any two or all three genes. 
(Mean ± SD, n=4 in each group, P<0.05, indicated as*). B, Effect of cIAP1, 
cIAP2 or Yap1 knockdown on tumor growth (Mean ± SD, n=4 in each group). 
According to the tumor volume measurements 17 days after transplantation, 
downregulation of cIAP1, cIAP2 and Yap1 by siRNA in mammary carcinoma 
cells decelerates tumor growth as compared to control (P=0.014, P=0.0056, 
and P=0.0091, respectively). Combination of cIAP1 and cIAP2, cIAP1 and 
Yap1, or all three genes further delays the tumor growth (P=0.0022, P=0.0073, 
and P=0.0069, n=4, respectively). 
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Figure 2.12 Efficacy of cIAP1, cIAp2 and Yap1 siRNA knock down.  
(Top) Relative mRNA expression of cIAP1, cIAP2 and Yap1 decreases from 1 
to 0.22 (cIAP1, P = 0.0003), to 0.25 (cIAP2 P =0.0002), and to 0.20 (Yap1, P = 
0.0001) after knockdown with respective siRNAs as compared to the control 
siRNA (Mean ± SD, n=4 in each group, P<0.05, is indicated as *). Western 
blot analysis (Bottom) demonstrates decreased levels cIAP1 and Yap1 
proteins after knockdown with specific siRNA as compared to the control 
scrambled siRNA. 
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2.5 Discussion 
Human sporadic cancers have a broad repertoire of genetic changes 
and understanding of their contributions to major pathways defects is of critical 
importance. Mouse models of human cancer have been shown to serve as 
useful systems to facilitate identification of genetic alterations essential for 
carcinogenesis by comparative oncogenomic approaches (Maser et al., 2007; 
Morrison and Kimble, 2006; Zender et al., 2006). During the past two decades 
it has become increasingly clear that different cancer phenotypes of mouse 
models may reflect distinct initiating genetic and epigenetic alterations (Cardiff 
et al., 2000). Indeed, combination of p53 and Brca1 somatic inactivation 
results in formation of tumors mimicking human BRCA1-mutated ER negative 
basal-like cancer (Liu et al., 2007). At the same time inactivation of p53 
together with E-cadherin leads to ER negative metastatic lobular mammary 
carcinoma (Derksen et al., 2006). Mammary neoplasms associated with p53 
deficiency alone were reported to be either ER negative (Liu et al., 2007) or 
both ER negative and positive, depending on MMTV or WAP promoter used to 
express Cre in deleter mouse strains (Lin et al., 2004).  
 Since available mammary epithelium-specific deleter strains express 
Cre in lymphoid and other tissues, we have established an additional MMTV-
Cre strain with a highly mammary epithelium-restrictive expression pattern. 
Interestingly, different from other MMTV-Cre based models and likely due to 
transgene positional effects, the cancers forming in our model are ER positive 
and have no or very limited non-luminal differentiation typical for such tumor 
types as adenomyoepthelial, adenosquamous and basal-like carcinomas. 
Thus interpretation of cancer phenotypes is also likely to be affected by 
variations in transgene expression patterns and transformation of distinct cell 
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lineages and their subpopulations.  
 Based on the expression of markers for luminal differentiation, such as 
ER and CK8, combined with p53 deficient status, as well as expression of 
Mad2 and cIAP2 (Frasor et al., 2009), this model may represent an attractive 
tool for studies of human luminal subtype B breast cancers (Hu et al., 2006; 
Sorlie et al., 2001). This model is also particularly amenable to further 
experiments because of responsiveness of mammary carcinomas to an 
estrogen antagonist as well as availability of established syngeneic mammary 
carcinoma cell lines. Considering the 50% frequency of mammary carcinomas 
and long latency period of carcinogenesis in p53ME-/- mice, they are particularly 
well suited for assessment of other endogenous and exogenous factors which 
are expected to accelerate carcinogenesis. 
 Our studies confirmed previous observations that sporadic inactivation 
of Rb alone is insufficient for the initiation of mammary carcinogenesis 
(Robinson et al., 2001). Furthermore, the use of a Cre-loxP approach allowed 
direct genetic demonstration that Rb loss-of-function, without inactivation of 
p107 and/or p130, leads to acceleration of mammary carcinogenesis 
associated with p53 inactivation. At least in part, this effect may be explained 
by increased proliferation rate of Rb-deficient neoplastic cells. 
 p53 and Rb pathways are extensively connected and their inactivation 
frequently cooperates during carcinogenesis presumably by abrogating E2F-
induced p53-mediated apoptosis or senescence (Sherr, 2004; Sherr and 
McCormick, 2002). Our study illuminates genomic instability as another 
mechanism of p53 and Rb cooperation. Genomic instability is a hallmark of 
most human cancers. Although much attention has been focused on the role 
of p53 in the maintenance of genomic stability, an accumulating body of 
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evidence indicates Rb as another important player (Knudsen et al., 2006). Rb 
inactivation has been shown to promote genomic instability by uncoupling cell 
cycle progression from mitotic control (Hernando et al., 2004) and by 
mediating DNA double strand break accumulation (Pickering and Kowalik, 
2006) in cell culture models. In vivo, Rb loss results in ectopic cell cycle, 
compromises ploidy control in mouse liver (Mayhew et al., 2005) and 
promotes hepatocarcinogenesis (Mayhew et al., 2007; Reed et al., 2009). Our 
study extends these observations by demonstrating higher levels of the E2F 
downstream target Mad2, higher rates of double strand DNA breaks and 
centrosome amplification and overall increase in chromosomal structural 
instability in mammary carcinomas deficient for both p53 and Rb. Further 
studies should determine if Rb loss leads to similar consequences in the 
normal mammary epithelium. It also remains to be demonstrated whether 
observed increase in phenotypical diversity and trend towards increase of 
cellular polymorphism and poorer differentiations in carcinomas of p53ME-/-
RbME-/- mice are a result of elevated genomic instability associated with Rb 
deficiency.  
 Using aCGH, we identified a number of recurrent genetic alterations in 
our mammary carcinoma models. It is likely that each of these alterations has 
individual contributions to carcinogenesis. The amplification of 9A1 locus is of 
a particular interest because it includes protooncogenes, such as cIAP1, 
cIAP2 and Yap1. cIAP1 and cIAP2 encoded proteins contain baculoviral IAP 
repeat (BIR) domain and are key regulators of apoptosis, cytokinesis, and 
signal transduction. Both genes are commonly amplified in many human 
cancers (reviewed in LaCasse et al., 2008). Yap1 contains a WW domain and 
binds to the SRC Homology 3 domain of the tyrosine kinase Yes. It has been 
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shown to be expressed in common solid tumors (Steinhardt et al., 2008) and 
to have tumorigenic properties in both liver (Zender et al., 2006) and breast 
cancer (Overholtzer et al., 2006). Considering the high frequency of 9A1 locus 
amplification in neoplasms of p53ME-/- mice, this model may prove to be very 
valuable for further studies of mechanisms involved in amplification of human 
orthologous genes on chromosome 11q22. 
 Amplification of both cIAP1 and Yap1 was observed in 4 out of 7 tumors 
in a transplantable mouse model of liver cancer based on transduction of p53 
deficient fetal hepatoblasts with Myc retrovirus (Zender et al., 2006). At the 
same time, amplification of cIAP1 and cIAP2, together with matrix 
metalloproteinase MMP13, was observed in 5 out of 41 osteosarcomas (Ma et 
al., 2009). Yap1 amplification was detected in one out of 15 mammary tumors 
of MMTV-Cre Brca1floxP/- p53+/- mice. However, amplification of Yap1 was 
detected in none of over 100 sporadic human breast cancers (Overholtzer et 
al., 2006). Our observations of E2F-mediated control of cIAP1, cIAP2 and 
Yap1 may explain how dysfunctional Rb/E2F pathway may substitute for 
recurrent amplification of these genes. Since alterations in the Rb pathway are 
quite common in mouse and human tumors, including mammary carcinomas, 
this mechanism may also explain differences in frequencies of cIAP1, cIAP2 
and Yap1 amplification among various tumor types.   
 Our results demonstrate that cIAP1, cIAP2 and Yap1 overexpression is 
critical for mammary carcinogenesis associated with p53 mutations. It is of 
interest that overexpression of cIAP2 has been recently reported to be 
associated with luminal subtype B of breast cancer (Frasor et al., 2009). 
Further studies will examine whether tumors of this subtype also overexpress 
cIAP1 and Yap1. Cooperation among cIAP1, cIAP2 and Yap1 in promoting 
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tumorigenicity observed in our work is consistent with previously reported 
cooperation between cIAP1 and Yap1 in hepatocarinogenesis (Zender et al., 
2006). Recently a broad variety of IAP molecule antagonists has been 
developed (LaCasse et al., 2008). Our results indicate that their application 
may be particularly effective in combination with downregulation of Yap1.  
 In summary, we established a new mouse model of sporadic ER 
positive luminal mammary carcinoma associated with p53 inactivation. We 
demonstrated that Rb deficiency accelerates mammary carcinogenesis and 
leads to increased genomic instability and to a different spectrum of recurrent 
genomic alterations. Of particular interest, genes of chromosome band 9A1, 
namely cIAP1, cIAP2 and Yap1, were shown to be important for mammary 
carcinogenesis. We proposed the E2F-mediated mechanism of their regulation 
and established cooperation among all three genes in promoting neoplastic 
growth. These observations provide the basis for further elucidation of 
cooperation of these genes in human cancers and lay the ground for rational 
development of therapeutic approaches in preclinical settings.  
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CHAPTER 3 
 
IDENTIFICATION AND CHARACTERIZATION OF CANCER STEM CELLS 
 
3.1 Abstract 
The leading explanation of the molecular and genetic heterogeneity of 
many cancers, including breast cancer, lies in the existence of a small highly 
tumorigenic subpopulation of cells called cancer stem cells (CSC). Since CSC 
represent an appealing target for development of more selective and efficient 
therapies their identification and characterization are critical for further 
advances of cancer research. To test if CSC exist in our model of mammary 
carcinoma associated with p53 and Rb deficiency cells expressing mammary 
stem cell markers CD24 and CD49f have been isolated and functionally 
characterized. As compared to CD24-CD49f- cell population far fewer of 
CD24+CD49f+ cells were required for orthotopic transplantation into the 
cleared mammary fat pad. Furthermore, as expected from CSC, CD24+CD49f+ 
cells yielded carcinomas much earlier and were able to reconstitute all tumor 
populations more efficiently than CD24-CD49f- cells in secondary and tertiary 
transplantations. Thus, CD24+CD49f+ cells were identified as CSC in our 
model. As compared to cancer non stem cells (CnSC, CD24-CD49f-) CSC had 
more stable genome according to lower  percentage of comet tail positive cell,  
lower expression of Mad2, and less DNA damage after γ irradiation. 
Phenotypic characterization of CSC identified high levels of cIAP1 and Aldh1 
which allowed determining their location by double immunostaining of tissue 
sections. To study the role of stem cell compartment in carcinogenesis and 
CSC initiation, we have isolated populations of mammary stem cells 
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(mammary repopulating units, MRU; CD24medCD49fhigh), and their progeny 
mammary colony-forming cells (Ma-CFC, CD24highCD49flow). We found that 
loss of p53 leads to an increase in the number and proliferation rate of Ma-
CFC but not MRU. Both parameters are further increased in Ma-CFC cell pool 
deficient for both p53 and Rb. Taken together, we demonstrate existence of 
CSC in our model and provide their initial characterization. Our study also 
identifies the mammary progenitor cells as the principle targets for malignant 
transformation, which subsequently leads to appearance of CSC, and 
suggests expansion of progenitor cell pool as a novel cooperative effect of p53 
and Rb inactivation on carcinogenesis.  
 
3.2 Introduction 
Cancers, whether solid or hematopoietic, from different patients often 
exhibit heterogeneity in morphology, genetic lesions, molecular profile, cell 
surface markers, cell proliferation kinetics, and response to therapy (Buerger 
et al., 1999a; Buerger et al., 1999b; Heppner and Miller, 1983). This 
heterogeneity may be due to cells with stem cell properties that can 
differentiate to yield different cell types within a tumor. Since the 19th century, it 
has been proposed that a subpopulation of neoplastic cells called cancer stem 
cells (CSC) may be responsible for initiating and propagating tumors (Nafus & 
Nikitin, 2009). CSC have stem cell-like properties that are thought to be 
responsible for the growth, progression, and recurrence of tumors (Clarke and 
Fuller, 2006). In 2003, Al-Hajj et al., first reported the isolation of cancer stem 
cells (CD44+ CD24-) from human breast cancer (Al-Hajj et al., 2003). This 
study also demonstrates that human breast cancer have a small proportion of 
cells that have the capacity to form a new tumor when serially xenografted in 
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NOD/SCID mice. To date, in humans, CSC have been identified in a number of 
malignancies, including leukemia (Bonnet and Dick, 1997; Lapidot et al., 1994), 
prostate cancer (Collins et al., 2005), brain tumors (Bao et al., 2006), ovarian 
cancer (Alvero et al., 2009; Szotek et al., 2006; Zhang et al., 2008b) and colon 
cancer (O'Brien et al., 2007; Ricci-Vitiani et al., 2007).  
The CSC subpopulation has been described in several mouse models 
of mammary carcinogenesis using different cell surface markers(Cho et al., 
2008; Vaillant et al., 2008; Zhang et al., 2008a). For example, in the MMTV-
Wnt1 mouse model of mammary cancer, a Thy1+CD24+ cancer cell population 
was found to be highly enriched for CSC relative to the non Thy1+CD24+ 
population (Cho et al., 2008). Vaillant and colleagues (2008) reported a 
different set of markers (CD29, CD24, and CD61) that can be used to isolate a 
CSC population which possesses a 20-fold enrichment tumor-initiating 
capacity in MMTV–Wnt1 mammary tumors (Vaillant et al., 2008). In addition, it 
is worth to note that CSC were not found in all mouse models of mammary 
tumors. In the well established MMTV–Erbb2 strain, no CSC subset could be 
identified using multiple different cell surface markers, suggesting a clonal 
evolution or stochastic model of carcinogenesis (Vaillant et al., 2008). In the 
p53-null mammary tumor model described by Zhang and colleagues (Zhang et 
al., 2008a), most of the tumors coexpressed luminal cell markers (CK8) and 
myoepithelial cell marker (CK14). A subpopulation of cells expressing high 
levels of CD24 and CD29 (Lin-CD24HCD29H), which accounts for 5-10% of 
total mammary epithelial cell population, has been identified as CSC by 
limiting dilution in cell culture mammosphere assays and subsequent 
transplantation in vivo (Zhang et al., 2008a). However, it should be noted that 
all experiments in this study were performed on tumors derived by 
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transplantation of p53-null mammary epithelium cells into cleared mammary 
fat pads. Thus, it remains to be demonstrated if the observed results can be 
reproduced in an autochthonous sporadic mouse model of mammary 
carcinogenesis.  
Alterations in p53 and Rb tumor suppressors or their pathways are 
common in human breast cancer. In addition, both p53 and Rb have important 
functions in stem cells. p53 has been shown to mediate the onset of 
senescence of endothelial progenitor cells, to negatively regulate proliferation 
and survival of neural stem cells, and to induce differentiation of embryonic 
stem cells (reviewed in Stingl and Caldas, 2007). Rb and its pathway are 
involved in control of stem cell cycle progression, senescence and tissue 
homeostasis (reviewed in Galderisi et al., 2006). Notably, p16/Rb and 
ARF/p53 pathways are extensively connected and may be coordinately 
regulated by Bmi-1. Bmi-1 has been shown to be required for maintenance 
and self-renewal of hematopoietic and neural stem and progenitor cells in 
mice and is involved in control of cell proliferation, survival and differentiation 
(reviewed in Valk-Lingbeek et al., 2004). Furthermore, it has been 
demonstrated that in a conditional mouse model of prostate cancer associated 
with p53 and Rb deficiency cancer cells show a heterogeneous phenotype 
and arise from the prostate stem cell compartment (Zhou et al., 2006; Zhou et 
al., 2007). However, it remains unclear whether mammary stem cells (MaSC) 
represent a preferential target for malignant transformation associated with 
p53 and/or Rb mutation.  
As discussed in Chapter 2, we generated mouse models of mammary 
carcinoma associated with p53 and Rb deficiency and demonstrated that 
these neoplasms are similar to human luminal type B, ER positive and 
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raloxifene-responsive breast cancer (Chapter 2). In this study, by using 
negative selection for cell lineage markers CD31, CD45 Ter119, CD140a, and 
positive selection for mammary stem cell markers CD24 and CD49f, we 
demonstrate that the mammary neoplasms in our model contain CSC. As 
compared to cancer non-stem cells (CnSC), CSC have a more stable genome. 
We further demonstrate that CSC have high expression of cIAP1 (cellular 
inhibitor of apoptosis 1) and Aldh1 and can be localized by double 
immunofluorescence on tissue sections. Finally, we demonstrate that p53 and 
Rb cooperatively control mammary progenitor cell proliferation and inactivation 
of these genes may result in carcinogenesis due to expansion of mutant 
progenitor cells.  
 
3.3 Materials and methods 
Mouse. Generation of p53ME-/-, RbME-/-, and p53ME-/- RbME-/- mice was 
described in Materials and Methods of Chapter 2. MMTV-Neu mice (Guy et al., 
1992) were obtained from the Jackson laboratory. The efficiency and tissue 
specificity of Cre-mediated recombination was examined by crossing 
MMTVCre transgenic founders with Tg(ACTB-Bgeo/GFP)21Lbe (Z/EG) mice 
(Novak et al., 2000) which express EGFP after Cre administration. 
Isolation of primary mammary epithelial cells and tumor cells. 
Normal mammary glands were dissected from 5 months old healthy FVB/N 
females. Mammary tumor tissue was from mouse model of mammary tumor 
with p53 and/or Rb deficiency. Procedure of isolation of primary mammary 
epithelial cells and tumor cells was described in Materials and Methods of 
Chapter 2. 
Cell labeling and Fluorescence Activated Cell Sorting (FACS) 
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analysis. Lineage positive cells were magnetically removed with CD31 
(endothelial cell), CD45 (hematopoietic cells), Ter119 (hematopoietic cells), 
and CD140a (stromal cells) antibodies using CELLection Biotin Binder Kit 
(Invitrogen, Carlsbad, CA, USA) after treatment of dissociated cells with 
respective biotinylated antibodies at concentration 1µg / 106 cell. The 
remaining cells were stained with PE-conjugated anti-CD24 antibody (BD, 
Franklin Lakes, NJ, USA) and FITC-conjugated anti-CD49f antibody (BD) or 
PE-conjugated and FITC-conjugated isotype control antibodies for 30 min on 
ice. Cells were washed twice with FACS buffer and resuspended into FACS 
buffer for cell sorting. Cell sorting was performed on a FACS Aria cell sorter 
(BD).  
Tumor cell transplantation and raloxifene treatment. This procedure 
was described in Materials and Methods of Chapter 2. 
Serial transplantations. To prove the self-renewal of CD24+ and 
CD49f+ population, sorted cells were serially transplanted following FACS and 
mammary fat pad transplantation described above. CD24+CD49f+ and CD24-
CD49f- cell fractions will be transplanted into the cleared mammary fat pad 
and grafts were collected after surgery, dissociated and subjected to sorting 
and transplantation as before. These experiments were accompanied by 
performing serial dilutions of transplanted cells in order to estimate number of 
clonogenic cells. Limiting dilution analysis was conducted by L-Calc™ 
software. The user guide of L-Calc™ can be found in 
http://www.stemcell.com/technical/lcalc02.pdf. 
Matrigel culture. Assay media was prepared by adding 49 ml of growth 
media (EpiCult-B, StemCell Technologies, Vancouver, BC, Canada) and 1 mL 
of matrigel (BD), and then cells were diluted to 1 x 104 cells/mL with assay 
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media. 500 μL of cell suspension was added to each well of the 48 well plate 
containing Matrigel, and then incubated at 37°C in a CO2 incubator. Clones 
were counted four days after culture. 
Immunohistochemical analyses. This procedure was described in 
Materials and Methods of Chapter 2. Primary antibodies used include: CK5 
(Covance, Berkeley, CA, USA, 1:1000), CK6, (Covance, 1:300), CK8 
(Developmental Studies Hybridoma Bank, University of Iowa, IW, USA, 1:50), 
SMA (Spring Bioscience, Fermont, CA, USA 1:300), and Phospha-Histone 
H2A.X (Ser139) (Cell signaling, Danvers, MA, USA, 1:100). All quantitative 
analyses were performed on digitally captured images as described in (Zhou 
et al., 2006).  
Western blot analysis. This procedure was described in Materials and 
Methods of Chapter 2. Primary antibody used include cIAP1 (Abcam, 
Cambridge, MA, USA, 1:300), Mad2 (Santa Cruz, Santa Cruz, CA, USA, 
1:200), and Gapdh (Advanced immunochemical Inc, Long Beach, CA, USA, 
1:1000). 
Neutral comet, Irradiation and H2AX staining assays. This 
procedure of neutral comet assay was described in Materials and Methods of 
Chapter 2. For tumor cell irradiation, isolated primary tumor cells were 
irradiated (10 Gray, PRIMUS Linear Accelerator, SIEMENS, Malvern, PA, 
USA), and then checked for DNA damage 6, 12, or 24 hours after irradiation 
by Phospha-Histone H2A.X (Ser139) staining.  
Real-time PCR. This procedure of real-time PCR was described in 
Materials and Methods of Chapter 2. cIAP1 and Mad2 TaqMan probes were 
from Applied Biosystems (Carlsbad, CA, USA).  
Cell proliferation and survival. For the proliferation assay, mice were 
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injected by i.p. with 5mg/ml bromodeoxyueidine (BrdU, Sigma, St. Louis, MO, 
USA) 20µl/g body weight. One hour after injection, mammary glands were 
dissected and processed for FACS sorting as described above. Sorted cells 
were spun onto microscope slides and stained for BrdU immunostaining as 
described previously (Flesken-Nikitin et al., 2003; Zhou et al., 2006; Zhou et 
al., 2007). For the apoptosis assay, Lin- cells were incubated with Annexin V-
FITC (BD), CD24-PE and CD49f-PE-Cy5 in dark for 30 min at 4oC and 
analyzed by FACS. A total of at least 50,000 cells were analyzed per sample.  
Statistical Analyses. All statistical analyses in this study were done 
using InStat 3.06 and Prism 5.01 software (GraphPad, Inc., San Diego, CA, 
USA) as described previously (Zhou et al., 2006). 
 
3.4 Results 
Identification of tumorigenic subpopulations with stem cell 
properties. According to flow cytometry analysis of mammary carcinomas 
from p53ME-/- and p53ME-/-RbME-/- mice (10 in each group), 8.8 ± 4.9% vs 11.8 ± 
5.6% for each group  of total tumor cell population were  CD24+CD49f+ cells, 
(Fig 3.1A). No significant differences were observed regarding to the 
percentage of CD24+CD49f+ cells in carcinomas from p53ME-/- and p53ME-/-
RbME-/- mice. When 5 x 103 cells of CD24+CD49f+ or CD24-CD49f- were 
cultured in Matrigel for 4 days, the CD24
+
CD49f
+ 
population generated 4 folds 
more clones than CD24- CD49f-  population (Fig 3.1C, D). We further tested 
the tumorigenic ability of these populations by transplanting cells into cleared 
mammary fat pad of 3 week old FVB mice. Transplantation of as few as one 
CD24+CD49f+ cell resulted in tumors formation 3 of 8 transplants, whereas no 
tumors were observed from 103 CD24-CD49f- cells (0 of 4 transplants) (Table 
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3.1). Twenty days after transplantation, 104 CD24+CD49f+ cells formed much 
larger tumors (Fig 3.1B left) than those of 104 CD24-CD49f-. Quantitative 
assessment showed that significant tumor volume difference (Fig 3.1B right, 
1.0 ± 0.18 cm3 VS 0.05 ± 0.08 cm3, CD24+CD49f+ VS CD24-CD49f-, 
Mean±SD, P<0.0001. 6 transplantation per group). According to calculations 
with L-Calc software and the data from Table 3.1, the frequency of tumorigenic 
cells was 1 in 9 in CD24+CD49f+ cell population, and 1 in 19,380 in CD24-
CD49f- cell population. Since self-renewal is a unique property of stem cells, it 
was tested by serial orthotopic transplantations of cell subpopulations. 
CD24+CD49f+ cells from the first round transplantation were able to 
reconstitute all tumor populations far more efficiently than CD24- CD49f- cells 
in secondary and tertiary transplantations (Table 3.1). In addition, transplant 
tumors generated by CD24+CD49f+ population displayed similar pathology and 
marker expression (CK8, SMA, CK5, and CK6) as compared with the original 
tumors (Fig 3.2), suggesting that these cells were able to generate the 
heterogeneous characteristics of the original tumor. Taken together these 
results demonstrate that CD24+CD49f+ cells meet the definition of CSC. 
Phenotypical properties of CSC. To evaluate functional status of 
isolated CSC population we have tested a number of markers. Cytosolic 
aldehyde dehydrogenase (Aldh), an enzyme implicated in retinoid metabolism 
and resistance of hematopoietic stem cells to alkylating agents such as 
cyclophosphamide (Hess et al., 2006). Aldh may have a role in early 
differentiation of stem cells through its role in oxidizing retinol to retinoic acid 
(Chute et al., 2006). It has been shown that mouse and human hematopoietic 
and neural stem and progenitor cells have high Aldh activity (Armstrong et al., 
2004; Hess et al., 2004). 
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Figure 3.2 Identification of cancer stem cell.   
A. Representative flow cytometry profiles of CD24 (PE) and CD49f (FITC) 
expression in freshly isolated mouse mammary tumor cells from p53ME-/- or 
p53
ME-/-
Rb
ME-/-
 mice. B. Cleared mammary fat pad transplantation with 10
4
 
CD24+CD49f+ (Left mouse) and CD24-CD49f- (Right mouse). 20 days after 
transplantation, double positive tumor cells form much larger tumors than that 
of double negative tumor cells. C and D. CD24+CD49f+ cell population form 
more clones than CD24-CD49f- cells in Matrigel (Mean ± SD, 86 ± 7 vs 21 ± 6, 
n=5, P=0.0003, * indicates  P<0.05).  
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Table 3.2 CSC and CnSC transplantation with serial dilution.   
              
# 
First round 
transplantation 
Second round 
transplantation 
Third round 
transplantation 
CSC CnSC CSC CnSC CSC CnSC 
104 
~14 days 
6/6 mice 
~30 days 
2/6 mice 
N/A N/A N/A N/A 
5 x 103 N/A 
~25 days 
1/4 mice 
N/A N/A N/A N/A 
2 x 103 
~12 days 
4/4 mice 
~35 days 
1/4 mice 
~12 days 
4/4 mice 
~25 days 
2/4 mice 
~10 days 
4/4 mice 
~18 days 
2/4 mice 
103 N/A 
~40 days 
0/4 mice 
~15 days 
4/4 mice 
~35 days 
1/4 mice 
~12 days 
4/4 mice 
~25 days 
1/4 mice 
3 x 102 
~22 days 
4/4 mice 
N/A N/A N/A N/A N/A 
102 
~25 days 
4/4 mice 
N/A 
~25 days 
3/4 mice 
~45 days 
0/4 mice 
~18 days 
3/4 mice 
~45 days 
0/4 mice 
20 
~ 30 days 
3/4 mice 
N/A N/A N/A N/A N/A 
1 
~30 days 
3/8 mice 
N/A 
~30 days 
2/4 mice 
N/A 
~25 days 
2/4 mice 
N/A 
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Figure 3.3 Immunohistochemical evaluation of mammary tumors after 
serial orthotopic transplantation.   
 Histological sections of mammary tumors: (A) primary tumor, (B) first, (C) 
second, and (D) third round of transplantation of 2X103 CD24+CD49f+ cells 
were stained with hematoxylin and eosin (HE), CK8, SMA, CK6 and CK5. 
CK8, SMA, CK6 and CK5, ABC method, counterstaining with hematoxylin. 
Calibration bar for all images: 100 µm.  
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Recently, ALDH1 expression and activity have been reported as 
markers of normal and malignant human mammary stem cells and a predictor 
of poor clinical outcome (Ginestier et al., 2007). In our study, over 90% CD24+ 
CD49f+ tumor cells were positive for Aldefluor, an indicator of Aldh1 enzymatic 
activity (Fig 3.3A), in all carcinoma analyzed (8 tumors from p53ME-/- and 8 
tumor from p53ME-/-RbME-/- mice). Thus our results confirmed Aldh as a CSC 
marker.  
cIAP1 (also known as Birc2) is a member of inhibitor of apoptosis (IAP) 
family. IAP family members are important regulators of cell death, and 
overexpression of IAPs predicts poor patient outcome in several types of 
cancer. cIAP1, containing the baculoviral IAP repeat domain, is an 
endogenous apoptosis inhibitor that interacts with caspases, suppressing 
apoptosis by preventing procaspase activation and inhibition of the enzymatic 
activities of caspases (Deveraux and Reed, 1999; LaCasse et al., 2008). Our 
studies demonstrated that overexpression of cIAP1 is essential for mammary 
carcinogenesis (Chapter 2). Interestingly we determined that particularly high 
levels of cIAP1 are present in CSC on both mRNA and protein level (Fig 3.3B 
and C). Therefore, cIAP1 can be used as a novel marker for CSC. Both CSC 
and CnSC are ER positive and CSC express well known stem cell regulators 
Gli2 and Wnt1 (Fig 3.3C).  
Localization of CSC population.  Studies of brain tumors have 
demonstrated that specialized perivascular niches contribute to the CSC long 
term growth and self-renewal by secreting factors (Calabrese et al., 2007; 
Charles et al.). To study if breast cancer also have similar vascular niche, we 
used blood vessel endothelial cell marker CD31 in combination with Aldh1 
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Figure 3.4 Characterization of cancer stem cells.  
A. Representative flow cytometry profiles of CD24 (PE) and CD49f (FITC) 
expression in freshly isolated mouse mammary tumor cells from p53ME-/- and 
p53ME-/- RbME-/- mice. Over 90% of CD24+CD49f+ tumor cells are Aldefluor 
positive. B. Real time PCR analysis demonstrated that cIAP1 mRNA are 
overexpressed in CSC (Mean ± SD, 22.8 ± 3.1 (CSC) vs 1.9 ± 0.1 (CnSC), 
n=5, P=0.0002, * indicates P<0.05). C. Protein expression of cIAP1, ER, Gli2 
and Wnt1 in CSC, CnSC and normal mammary epithelia cells (WT). cIAP1 
protein is overexpressed in CSC, as compared to CnSC and WT. Both CSC 
and CnSC are ER positive. Gli2 and Wnt1 are highly expressed in CSC as 
compared to CnSC.  
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Figure 3.5 Localization of cancer stem cells.  
A. Double fluorescence staining with Aldh1 and CD31. Location of Aldh1 
positive cells is associated with CD31 positive cells (Top and Middle). Aldh1 
negative cells are not associated with CD31 positive cells (Bottom). B. Double 
fluorescence staining with cIAP1 and CD31. Location of cIAP1 positive cells is 
associated with CD31 positive cells (Top and Middle). cIAP1 negative cells are 
not associated with CD31 positive cells (Bottom). C. Double fluorescence 
staining with Aldh1 and cIAP1. Aldh1 overexpressed cells are co-localized with 
cIAP1 overexpressed cells very well. Arrows show positive cells. 
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and/or cIAP1 antibodies. Double fluorescence staining with Aldh1 and CD31, 
or cIAP1 and CD31 showed that Aldh1 or cIAP1 positive cells are associated 
with CD31 positive cells (Fig 3.4A and B). While Aldh1 or cIAP1 negative cells 
are not associated with CD31 positive cells (Fig 3.4A and B). As expected, 
Aldh1 and cIAP1 positive cells are co-localized (>75%) in the most of cases 
(Fig 3.4C). Total 6 tumors were analyzed. These observations may indicate 
that breast CSC have a similar vascular niche to that in brain tumors.     
CSC have higher genomic stability as compared to CnSC. Similar 
to normal stem cells CSC may have higher levels of resistance to genotoxic 
factor. Indeed it has been reported that CSC are frequently more resistant to 
irradiation and chemotherapy (reviewed in Rich and Bao, 2007). To test if CSC 
have higher genomic stability as compared to CnSC, we examined Mad2 
expression and performed comet tail assay. Mad2 has been shown to mediate 
DNA double strand break accumulation and contribute to mitotic defects and 
genomic instability (Hernando et al., 2004; Pickering and Kowalik, 2006). 
Neutral comet tail assay is used to identify DNA double strand break. CSC had 
significantly lower Mad2 expression on both mRNA and protein level, and less 
comet tail positive cells (Fig 3.5A, B and C). Therefore, our observations 
indicate that CSC have relatively more stable genome than CnSC. 
To test CSC DNA damage response to γ irradiation primary mammary 
carcinoma cells were exposed to a dose of 10 Gray. 6, 12 and 24 hours after 
irradiation to separate CSC and CnSC populations, and stained for 
Phosphorylated H2AX, a marker for DNA damage. CSC have lower 
percentage of phosphorylated H2AX positive cells than CnSC at 0 hour (Fig 
3.5D).  Percentage of H2AX positive CSC has no change until 12 hours after 
irradiation, while increased percentage of H2AX positive CnSC is detected  
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Figure 3.6 CSC have higher genomic stability as compared to CnSC.  
CSC have lower Mad2 expression than CnSC in both mRNA (A, (Mean ± SD, 
2.45 ± 0.12 VS 3.78 ± 0.11, n=4, P=0.001, * indicated P<0.05).) and protein 
level (B). C. CSC have lower percentage of comet tail positive cells than CnSC 
(Mean ± SD, 15.1 ± 1.2 VS 17.8 ± 1.3, n=4, P=0.043, * indicated P<0.05). D. 
Cells treated with irradiation will cause DNA damage. Without irradiation, CSC 
have less DNA damage than CnSC, as indicated by less percentage of 
positive phosphorylated H2AX cells (12 ± 2 VS 21 ± 3.6, n=4, p=0.013). After 
irradiation, percentage of positive phosphorylated H2Ax cell is 9 ± 1 VS 37 ± 
4.6 (CSC VS CnSC, Mean ± SD, n=4, P=0.0083), 20 ± 1.7 VS 49 ± 6 
(P=0.0023), and 46.7 ± 11.9 VS 63.3 ± 2.9 (P=0.026) at 6 hours, 12 hours and 
24 hours, respectively. 
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already at 6 hours after irradiation. Eventually, Percentage of H2AX positive 
CSC increased at 12 and 24 hours after irradiation, but was less pronounced 
than that of CnSC at all time points, indicating that CSC are likely to be more  
resistant to irradiation therapy.   
Cre expression in mammary stem and colony-forming cells. 
Recently it has been demonstrated that mammary stem cells, mammary 
repopulating units (MRU) and their progeny mammary colony-forming cells 
(Ma-CFC) can be successfully isolated by negative selection for lineage 
markers (Lin-) of hematopoietic (CD45 and Ter119), endothelial (CD31) and 
stromal (CD140a) cells followed by positive selection for mammary stem cell 
markers CD24 and CD49f or CD29 (reviewed in Stingl and Caldas, 2007). We 
were able to reproduce those experiments and confirmed that MRU, and to 
some extent Ma-CFC were able to form mammary gland after transplantation 
into the cleared mammary fad pat (Fig 3.6). 
To study the role of stem cells in mammary carcinogenesis, we first 
assessed efficiency of Cre-mediated recombination in MRU and Ma-CFC. 
MMTVCre mice were crossed with Z/EG reporter mice, in which the EGFP 
expression indicates Cre activity. According to tri-color FACS analysis of 
mammary epithelial cells about 2.8% of MRU (CD24medCD49fhigh) and 3.4% of 
Ma-CFC (CD24highCD49flow) were EGFP positive in MMTV-Cre EGL mice (Fig 
3.7). Therefore, Cre is expressed in both MRU and Ma-CFC.  
 Inactivation of p53 and Rb cooperate in increasing Ma-CFC 
population. To determine the role of p53 and Rb in control of MRU and Ma-
CFC, MRU and Ma-CFC were isolated from FVB, MMTV-Neu, p53ME-/-, RbME-/- 
and p53ME-/- RbME-/- 4 to 6 months old female mice and subjected to 
quantitative flow cytometry analysis (Fig 3.8). There was no significant  
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Figure 3.7 Isolation and characterization of MRU and Ma-CFC.  
A. Representative flow cytometry profiles of CD24 (PE) and CD49f (FITC) 
expression in freshly isolated mouse mammary epithelia cells. MRU and Ma-
CFC account for 0.3% and 1.3% of total cell population, respectively. B and C. 
Whole mount staining of the mammary gland generated within 4 weeks by 
transplantation of 1000 MRU and 5000 Ma-CFC, respectively, into the cleared 
mammary fat pad. 
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Figure 3.8 Cre expression in MRU and Ma-CFC.  
A, Flow cytometry profiles of CD24 (PE) and CD49f (PE-Cy5) expression in 
freshly isolated mouse mammary cells from MMTVCre Z/EG (Top) and Z/EG 
(Bottom) mice. B, Comparison of EGFP expression in MRU (Top) and Ma-
CFC (Bottom) of MMTVCre Z/EG and Z/EG nulliparous mice. C, EGFP 
expression profiles in MRU (Left) and Ma-CFC (Right) of MMTVCre Z/EG and 
Z/EG nulliparous mice. All experiments were performed twice. 
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Figure 3.9 Effects of p53 and Rb inactivation on MRU and Ma-CFC pools 
in the mammary epithelium.  
A, Examples of flow cytometric staining patterns of freshly isolated mouse 
mammary cells in FVB, MMTV-Neu, p53ME-/-, RbME-/-, and p53ME-/-RbME-/-  mice. 
MRU, green gates; Ma-CFC, black gates. B, Percentage of MRU (Left) and 
Ma-CFC (Right) in mouse mammary glands (Mean ± SD). No significant 
differences were found among all MRU groups (two-tailed P > 0.05, n≥3). As 
compared to FVB control (n=7) more Ma-CFC were found in mammary glands 
from p53ME-/- (n=4, P<0.0001), RbME-/- (n=3, P=0.0003) and p53ME-/-RbME-/-   
(n=6, P<0.0001). Star, statistically significant differences. 
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difference in the number of MRU in all tested groups. In agreement with 
previous results indicating that Neu usually targets more differentiated luminal  
cells (Li et al., 2003; Liu et al., 2004; Liu et al., 2007), the number of Ma-CFC 
isolated from MMTV-Neu was close to that of Ma-CFC isolated from FVB 
mice. However, inactivation of either p53 or Rb significantly increased the 
number of Ma-CFC compared to FVB and MMTV-Neu mice (p < 0.05). Loss of 
both p53 and Rb led to further elevation in number of Ma-CFC. Thus, p53 and 
Rb are likely to cooperate in controlling the size of Ma-CFC but not MRU 
population.  
Loss of p53 and Rb preferentially increases Ma-CFC proliferation. 
To further investigate the mechanisms of by which p53 and Rb increase the 
number of Ma-CFC, cell proliferation (BrdU incorporation, Fig. 3.9A) and cell 
apoptosis (Annexin V staining, Fig. 3.9B) assays were preformed on sorted 
MRU and Ma-CFC cells. Inactivation of p53 and/or Rb did not affect MRU 
proliferation. However, loss of either p53 or Rb led to 3-fold increased in Ma-
CFC proliferation (P=0.0004 and P=0.001, respectively). Inactivation of both 
p53 and Rb elevated Ma-CFC proliferation by 5 times (P=0.0024). At the same 
time, loss of p53 or Rb alone or together had no effects on apoptosis of MRU 
and Ma-CFC. Thus, lack of p53 and Rb leads to increase in size of Ma-CFC 
population mainly by elevating cell proliferation. 
 
3.5 Discussion 
During recent years there have been extensive efforts to identify, 
isolate, and target CSC in human cancers. However, such fundamental 
questions as specific contributions of stem cell-related molecular mechanisms 
to pathogenesis of various cancers, the role of normal stem cell compartment  
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Figure 3.10 Quantitative assessment of proliferation and apoptotic rates 
of MRU and Ma-CFC.  
No significant differences (two-tailed P > 0.05, n≥3) among groups were found 
in proliferation rates of MRU (A) and apoptotic rates of MRUs (B) and Ma-CFC 
(D). C, As compared to FVB control (n=4) more proliferating Ma-CFC were 
found in mammary glands from p53
ME-/-
 (n=4, P=0.0004), Rb
ME-/-
 (n=4, 
P=0.001) and p53ME-/-RbME-/-   (n=4, P=0.0024). Star, statistically significant 
differences. 
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in cancer initiation and effects of immune system and microenvironment on 
stem cells during carcinogenesis have only just begun to be addressed. 
Our autochthonous sporadic mouse models of breast cancer have 
similar hisopathological features to the human breast cancer (Luminal type B, 
ER positive and raloxifene responsive), and are expected to recapitulate the 
genetics and molecular characteristics as well as therapeutic responses of 
human breast cancer (Chapter 2). Using CD24 and CD49f (Lin-CD24+CD49f+), 
we identified and functionally tested CSC by both Matrigel cell culture assay 
and cleared mammary fat pad transplantation in vivo assay. Furthermore, we 
have found that CSC show more stable genome and exhibit γ-irradiation-
induced DNA damage as compared to CnSC. Our observations are consistent 
with many other studies demonstrating that traditional therapies do not 
efficiently target CSC, and cancer commonly relapses after first round of 
treatment. For example, it was observed that glioma stem cells (CD133+) 
were enriched after irradiation (Bao et al., 2006). The CD133+ cells had higher 
DNA damage checkpoint activation and more efficient DNA repair relative to 
the CD133− cells. In addition, the radioresistance of CD133+ cells can be 
restored by inhibiting the cell cycle checkpoint, using a Chk1/Chk2 inhibitor. 
Another group reported that CD133+ glioma cells are more resistant than 
CD133− cells to several chemotherapeutic agents (Liu et al., 2006). They 
showed that this resistance could be attributed to increases in anti-apoptotic 
factors, including FLIP, BCL-2 and BCL-XL. Consistently, we have found that 
CSC overexpress protooncogene cIAP1, the key regulator of apoptosis, 
cytokinesis, and signal transduction and are commonly amplified in many 
cancers (reviewed in LaCasse et al., 2008). CSC also have Mad2 down-
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regulation, which mediate DNA double strand break accumulation and 
contribute to mitotic defects and genomic instability (Pickering and Kowalik, 
2006). Furthermore, some other studies have shown that CSC possess low 
levels of reactive oxygen species (ROS), which normally catalyze apoptosis 
following radiotherapy (Diehn et al., 2009; Rich & Bao, 2007). Targeting the 
DNA damage checkpoint response and ROS pathways in CSC may overcome 
radioresistance and provide a therapeutic model for cancer. 
The maintenance of stem cell prosperities is critically affected by the 
microenvironment called the niche. The niche is composed of surrounding 
cells in a special location that functions to maintain the stem cells. The cells of 
the niche generate extrinsic factors that control stem cell number, proliferation 
and differentiation (Sneddon and Werb, 2007). In recent years, niches have 
been identified for mammalian stem cells in the intestinal, neural, epidermal, 
and hematopoietic systems (Sneddon and Werb, 2007). It was reported that 
niches may be  involved in CSC regulation, tumor invasion and metastasis, 
oxidative stress response (Iwasaki and Suda, 2009). Work in the 
hematopoietic system demonstrated that specialized microenvironments of 
bone marrow endothelial cells appear to be required for the homing and 
engraftment of both normal hematopoietic stem cells and leukemic cells 
(Sipkins et al., 2005). Recently, in solid tumors, perivascular niche was 
reported in which endothelial cells in brain tumors contribute to the CSC long 
term growth and self-renewal by secreting factors, such as nitric oxide 
(Calabrese et al., 2007; Charles et al.). Nitric oxide secreted from endothelial 
cells promotes a stem cell-like character in cells present in the perivascular 
niche (Charles et al.). In addition, by an ectopic transplantation assay, it has 
been demonstrated that microenvironment may play an essential role in 
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controlling cancer formation in the prostatic stem cell compartment (Zhou et 
al., 2007). We localized mammary CSC by using two markers, Aldh1 and 
cIAP1. Localization of CSC in tumor provides a tool to further study the CSC 
niche, and effects of microenvironment on self-renewal and differentiation of 
CSC.   
CSC and normal stem cells share several other important properties, 
including their active expression of telomerase, the activation of antiapoptotic 
pathways, and an increased ability to migrate and metastasize. In addition, 
CSC resemble the normal stem cells of corresponding tissue of origin. For 
example, mammary CSC express CD24 and CD29/CD49f that mark normal 
mammary stem cells (Zhang et al., 2008a). Interestingly, our results indicate 
that expansion of mammary precursor cells (Ma-CFC) but not stem cells 
(MRU) precedes development of overt neoplasms associated with p53 and Rb 
deficiency. Such an expansion may represent an essential step for 
accumulation of secondary mutations necessary for further progression and 
selection of neoplastic traits. Importantly, cooperation p53 and Rb in control of 
Ma-CFC population may represent an additional tumor suppressive 
mechanism which may explain frequent coincidence of alterations in these 
genes or their respective pathways. 
Expression of Ma-CFC markers is associated with colony-forming cells 
of the luminal lineage (reviewed in Stingl and Caldas, 2007). Notably, our 
mouse models of mammary carcinoma have hisopathological features that are 
similar to those of the human luminal type B breast cancer. Thus, they may be 
particularly well suited for future studies to determine how p53 and Rb may 
specifically control luminal-restricted progenitors.  
In summary, we demonstrated that in addition to previously established 
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similarities with human disease, our mouse model of mammary carcinoma 
contains CSC which are likely to arise from the expanded pool of luminal 
progenitors. We also developed tools for detection of CSC in tissues and 
demonstrated that CSC have higher genomic stability as compared to CnSC. 
Thus our mouse model is well suited for development of therapeutics that 
directly target CSC.  
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CHAPTER 4 
 
THE ROLE OF MIR-376B/MIR-467B-CIAP1/2 PATHWAY IN MAMMARY 
CANCER STEM CELLS 
 
4.1 Abstract 
Cancer stem cells (CSC) are a subpopulation of tumor cells that are 
derived from transformed stem cells, progenitor cells, or more differentiated 
proliferating cells. These cells possess both the ability to self-renew to 
repopulate tumors and to differentiate to form heterogeneous populations of 
cells. MicroRNAs are a class of small RNAs whose ability to regulate gene 
expression makes them crucial in many cellular processes, which led us to ask 
whether miRNAs may be involved in the regulation of CSC. CSC were isolated 
from a mouse model of mammary carcinoma associated with p53 and/or Rb 
deficiency by using the CD24 and CD49f cell surface markers. Microarray 
analysis identified that miR-376b and miR-467b, downregulated in both CSC 
and Mammary Stem Cells (MaSC) as compared to Cancer non Stem Cells 
(CnSC) and normal differentiated mammary epithelial cells. Using 
bioinformatics and luciferase reporter assay, we identified proto-oncogenes 
Cellular Inhibitors of Apoptosis (cIAP) 1 and 2 as targets of both miRNAs. It 
was determined that cIAP1/2 are overexpressed in CSC as compared to 
CnSC, and  miR-376b and miR-467b reconstitution leads to decreased levels 
of cIAP1/2 according to quantitative real time PCR and western blotting. 
Accordingly, miR-376b and miR-467b reconstitution, as well as cIAP1/2 
siRNA-mediated knockdown decrease mammosphere formation. These 
studies indicate that miR-376b/ miR-467b - cIAP1/2 pathway is important for 
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CSC self-renewal and may represent a new target for development of new 
therapeutic approaches. 
 
4.2 Introduction 
Cancer stem cells (CSC) are a subpopulation of tumor cells that are 
derived from transformed stem cells, progenitor cells, or more differentiated 
proliferating cells. The CSC hypothesis postulates that tumors are maintained 
by a population of neoplastic cells with stem cell properties such as the ability 
to self-renew and to produce a progenitor cell that can proliferate and 
differentiate in one asymmetric cell division (Wicha et al., 2006). Human CSC 
have been identified in a variety of cancer types, including breast cancer. 
There are still questions about the molecular mechanisms of CSC formation 
and self-renewal as well as CSC interaction with their microenvironment. 
Mouse models that remove the potential cross-species barriers to 
xenotransplantation represent an important tool for studying these questions. 
In the context of mammary tumors, the CSC subpopulation has been 
described in several mouse models of mammary carcinogenesis using 
different cell surface markers (Cho et al., 2008; Vaillant et al., 2008; Zhang et 
al., 2008). 
MicroRNAs (miRNA) are small (around 22 nucleotides) linear fragments 
of RNA that serve as post-transcriptional regulators of gene expression. 
Initially thought to represent a rare class of regulatory molecules, the number 
of metazoan miRNA is now predicted to be upwards of 500 unique molecules 
(Bartel, 2009). Many miRNAs have been implicated in various human cancers. 
Tumor cells seem to undergo a general change of global miRNA expression, 
which promotes transformation. miR-15a and miR-16-1 loss has been found in 
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chronic lymphocytic leukemia, prostate cancer and myeloma, resulting in 
induce apoptosis and inhibit carcinogenesis (Cimmino et al., 2005). The loss 
of the miR-34 family which induces apoptosis has been found in pancreatic, 
colon, breast and liver cancers. Additionally, the loss of let-7, miR-29, miR-
145, miR-221, miR-222, miR-21, miR-372 and miR-373 are common in human 
cancers, and inhibit carcinogenesis (reviewed in (Croce, 2009)). Furthermore, 
overexpression of miRNAs has been observed in various human cancers. The 
first miRNAs that were found to be overexpressed in cancers were miR-155 
and miR-17-92 cluster in B cell lymphomas. Importantly, some miRNAs have 
both oncogenes and tumor suppressor gene function, depending on tissue or 
cell type. For example, miR-221 and miR-222 target an oncogene, KIT, and 
inhibit the growth of erythroblastic leukaemia, and function as tumor 
suppressors in erythroblastic cells. However they also target at least four 
tumor suppressors- PTEN, p27, p57 and TIMP3, and function as oncogenes 
(Croce, 2009). 
MicroRNAs have been shown to influence stem cell self-renewal. 
Firstly, dicer, an endoribonuclease, cleaves pre-microRNA into short double 
strand RNA. Mouse dicer mutants were embryonic lethal and exhibited 
embryonic stem (ES) cell division and proliferation defects. Furthermore, many 
miRNA have been identified as “ES specific” indicating that these miRNA may 
play a unique role in maintaining the pluripotency of stem cells (Zhang et al., 
2006). miRNAs have also been implicated in the maintenance of mammary 
epithelial progenitor cells. 50 miRNAs were shown to be differentially 
expressed between progenitors and differentiated cells. In particular, miR-let7c 
causes a decrease in the self-renewing compartment of mammary epithelial 
cells. Furthermore, the self-renewing compartment generated much fewer 
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mammospheres after treatment with precursor miR-let-7c molecules (Ibarra et 
al., 2007). miR-10b has been implicated as a causal contributor to breast 
cancer invasion and metastasis.  Regulated by the transcription factor TWIST, 
high miR-10b expression correlates to greater metastasis via the upregulation 
of the pro-metastatic gene RHOC (Ma et al., 2007). In addition, a set of 
miRNAs have been recently identified that are not expressed in either 
mammary epithelial stem cells or in enriched breast cancer stem cells 
(Shimono et al., 2009). The same group also found that overexpression of 
miR-200c either in normal stem cells or in cancer stem cells, reduced their 
clonogenic and tumor initiating activities. 
To identify and understand the function of specific microRNAs that may 
be important for CSC functions we used a mouse model of mammary 
carcinoma associated with p53 deficiency. In this model, mammary neoplasms 
are similar to human Luminal B type, ER positive, and raloxifene responsive 
breast cancer (Chapter 2). Previously, CSC (CD24+CD49f+) have been 
identified and characterized in these tumors (Chapter 3). Given the above 
mouse model, we first isolated CSC and CnSC via FACS followed by 
characterization of the miRNA expression profile via microarray analysis. miR-
376b and miR-467b were among the most down-regulated miRNAs, and were 
selected to further study. After verifying the expression of these miRNAs using 
real time PCR, we determined that miR-376b and miR-467b may regulate 
cIAP1 and cIAP2 by bioinformatics approach. This possibility has been further 
confirmed by measurement of mRNA and protein levels of target genes after 
reconstitution of miRNAs and use of luciferase vectors that carry the putative 
miRNA binding site within the 3’ UTR of target genes. Finally, we performed 
proliferation, apoptosis and self-renewal to determine the role of miR-376b and 
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miR467b, and their target genes cIAP1 and cIAP2 in CSC.  
 
4.3 Materials and methods  
Isolation of primary mammary epithelial cells and tumor cells. The 
procedure was described in Materials and Methods of Chapter 2 and 3. 
Cell culture. The procedure was described in Materials and Methods of 
Chapter 2. 
Cell labeling and Fluorescence Activated Cell Sorting (FACS) 
analysis. The procedure was described in Materials and Methods of Chapter 
3. 
Mammosphere assay. Dissociated mammary epithelial cells are 
counted by hemocytometer and suspended in 1:1 Matrigel (BD, Franklin 
Lakes, NJ, USA) /mammary epithelial growth medium (MEGM, Lonza, Basel, 
Switzerland) in a total volume of 100 μl. Samples are plated around the rims of 
wells in a 12-well plate and allowed to solidify at 37°C for 10 minutes. After 
that, 1 ml of MEGM is added to each well and replenished every 3 days. Ten 
days after plating, spheres with a diameter over 40 μm are counted. 
RNA isolation and enrichment of small RNA. RNA was isolated from 
the FACS sorted cells using the mirVana™ miRNA Isolation Kit from 
Ambion/Applied Biosystems (Foster City, CA, USA). The protocol was 
followed according to manufacturers’ recommendations. The concentration of 
RNA was measured using a Nanodrop (Nanodrop Technologies, Wilmington, 
DE). RNA was stored at -80oC until needed. For further study of the microRNA 
population, Flash PAGE (Ambion) was used to enrich small RNAs (<70 bp). 
Total RNA was migrated through a miniature electrophoretic acrylamide gel, 
and the small RNAs, which migrated first out of the gel, were collected. The 
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concentration of small RNAs was checked using Nanodrop and RNA was 
prepared for microarray analysis. 
Microarray. The small RNAs were labeled using Mirus LabelIT miRNA 
labeling kit (Mirus, Madison, WI, USA). The fluorescent dye used in the 
labeling reaction was Cy5™. Manufacturer’s protocol was followed, ensuring 
that a minimum of 50 ng of small RNAs were used for each reaction. Labeled 
RNA was provided to the Microarray Core Facility at Cornell University. 
CombiMatrix MicroRNA 4X2K microarrays (CombiMatrix, Mukilteo, WI, USA), 
containing probes against mouse miRNAs (release 8.1 of the Sanger 
database) were used for hybridization. Array data was analyzed by Cornell 
Microarray Core Facility.  
Real-time PCR. Total cDNA was made using an oligo-dT primed 
reverse transcription reaction. The Superscript™ III First Strand RT kit 
(Invitrogen, Carlsbad, CA, USA) was used to make cDNA from the poly-
adenylated mRNA population, as described by the protocol. Generating cDNA 
from very small fragments of RNA required a special RT system, developed by 
Applied Biosystems. A stem-loop sequence-specific primer hybridized to the 3’ 
end of the miRNA and first strand cDNA was synthesized. TaqMan™ Gene 
Expression Assays were purchased from ABI for each gene of interest as well 
as our miRNA of interest. The endogenous controls used for miRNA and 
mRNA calibration were RNU6B and Gapdh, respectively (ABI). The 
manufacturer’s protocol was followed precisely. Each sample was replicated 
four times. Optical 96-well plates (ABI) were used for real-time quantification of 
PCR using a 7500 Real Time PCR System (ABI). Fold change in gene 
expression was calculated as per the 2-∆∆Ct method.   
miRNA precursors. Precursor molecules (pre-miRNA) for miR-376b, 
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miR-467b, and miR-scramble were purchased (Ambion). The miR-scramble 
represents a precursor miRNA molecule that is processed within the cell, but 
does not target any identified 3’UTRs. These molecules (20 nM into each well 
of a 24-well plate) were transfected into cells using Lipofectamine2000™ 
(Invitrogen) reagent, in order to upregulate the cellular concentration of the 
miRNA of interest. Following 48 hours of this treatment, the expression levels 
of target mRNA were checked using qPCR, the levels of cellular proteins were 
checked using western blotting, proliferation and apoptosis were measured 
using BrdU incorporation and caspase-3 staining respectively.   
Western blot analysis. The procedure was described in Materials and 
Methods of Chapter 2. Primary antibody used include cIAP1 (Abcam, 
Cambridge, MA, USA, 1:300), Mad2 (Santa Cruz, Santa Cruz, CA, USA, 
1:200), and Gapdh (Advanced immunochemical Inc, Long Beach, CA, USA, 
1:1000). 
Luciferase assays.  Luciferase vectors (Ambion) contained multiple 
cloning sites (MCSs) at the 3’ end of the luciferase gene. This enabled us to 
clone 3’ UTRs of our genes of interest into the MCS of the luciferase vector. 
Upon cloning, the luciferase vector + 3’UTR was transfected into cells using 
Lipofectamine2000™ along with the precursor miRNA molecules. If the 
miRNA were able to target a specific 3’UTR, a decrease in luciferase 
expression due to translational inhibition is observed.  
Cloning. The luciferase vector (pMIR-REPORT™ miRNA Expression 
Reporter Vector System, Ambion) was provided as a glycerol stock solution in 
E. coli (Fig. 4.1). The plasmid was isolated from the bacteria using Midi preps 
(QIAGEN, Germantown, MD, USA) to yield a large quantity of plasmid. The 
luciferase vector was double digested with SpeI and MluI (NEB) in NEB Buffer 
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2 with added BSA for 3 hours at 37oC. Simultaneously, PCR was performed 
on genomic wild-type DNA (from mouse FVB/N mammary epithelial cells) in 
order to clone the 3’UTRs of Birc2, and Birc3. Primers were designed, using 
IDTDNA primer design software, with insertions of the SpeI (ACTAGT) and 
MluI (ACGCGT) restriction sequences (Table 1). The PCR products were then 
double digested with MluI and SpeI at 37oC for 3 hours. Digested products 
were run on a 1% agarose gel with EtBr and extracted using a Gel Purification 
kit (QIAGEN). The gel purified products were used in a ligation reaction 
overnight at room temperature. Ligated vectors were transformed into TOP10 
E. coli (Invitrogen, Carlsbad, CA) as per manufacturer’s protocol and plated 
onto LB agar plates with 100 μg/mL of ampicillin overnight at 37oC. Four 
colonies were picked for each ligation reaction. DNA was also sequenced for 
each of the four colonies for the three 3’UTRs (12 samples total) using the 
following primer: 5'– AGGCGATTAAGTTGGGTA–3'. This primer sequenced 
the 3’UTR of each insert from the 3’ to 5’ end of the 3’ UTR. Plasmid DNA and 
primer were combined and provided to the DNA Sequencing facility. 
Sequencing was performed using Big Dye terminator chemistry on an ABI 
3730 Automated DNA Analyzer. Sequence results were analyzed with 
Chromas (Technelysium, Holland Park, Australia) software.  
Luciferase screening. 24-well plates were used to culture tumor cells 
to 50% confluence in complete medium. Transfections were carried out 
according to the protocol provided for Lipofectamine 2000™ (Invitrogen) 
transfection using OptiMEM™ medium (Invitrogen). After 48 hours of 
treatment, the media was aspirated from the 24 well plates and cells were 
washed with 1xPBS. PBS was aspirated and cells were lysed using the lysis 
buffer provided in the Luciferase Assay System (Promega, Madison, WI). 10  
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Figure 4.11  Luciferase expression vector driven by CMV promoter.  
Total size is 6470 bp without 3’ UTR inserts at the 3’ end of the luciferase 
gene. Plasmid encodes ampicillin and puromycin resistance.  
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Table 4.1 PCR Primers for 3’ UTR amplification.   
 
Primers used to amplify the 3’ UTR of Birc2, Birc3, and E2F2 respectively. The 
SpeI sequence is in blue, the MluI sequence is in red.  
 
 
 
 
 
 
 
 
Gene Sequence 
Birc2 Forward 5’ AAAACTAGTTGGTCTGAAAGTATTGTTGGACA 3’ 
Birc2 Reverse 5’ AAAACGCGTGCATACATCCCTGCACACAC 3’ 
Birc3 Forward 5’ AAAACTAGTTCAGCCAGGAGGAAGTTCAC 3’ 
Birc3 Reverse 5’ AAAACGCGTTCATATCCCTAAAATGTCATCCAA 3’ 
E2F2 Forward 5’ AAAACTAGTGCTCTCTTCCAGCCTTCCTT 3’ 
E2F2 Reverse 5’ AAAACGCGTCTTTGGGACAGTGGGTGTTT 3’ 
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μL of lysed cells were added to 100 μL of luciferase reagent, causing 
luciferase to catalyze its substrate into a light emitting compound. The intensity 
of light emitted was measured using a luminometer (Turner Biosystems, 
Sunnyvale, CA, USA). Each reaction was conducted in triplicate, yielding three 
theoretically identical readings for each sample. 
 Proliferation assay and apoptosis assay. Both procedures were 
described in Materials and Methods of Chapter 2. 
Bioinformatics. Bioinformatics analysis was performed using a variety 
of online software algorithms. Of utmost importance was the Sanger Institute’s 
mirBase website release 12.0. This database contained the pre-miR and 
mature miRNA sequences along with genome information and citations for 
known miRNA. miRNA target searches were employed to identify genes that 
were potentially targeted by our miRNA of interest. These included Miranda, 
Targetscan, and Targetrank.  
Statistical Analyses. All statistical analyses in this study were done 
using InStat 3.06 and Prism 5.01 software (GraphPad, Inc., San Diego, CA, 
USA) as described previously (Zhou et al., 2006). 
 
4.4 Results  
Microarray analysis. The results of the microarray analysis yielded five 
most upregulated and downregulated miRNA in the CSC population as 
compared to the CnSC population (Table 4.2). Two of the most downregulated 
miRNAs, miR-376b and miR-467b were chosen for further study (Table 4.3). 
The results of the microarray were validated using stem-loop reverse 
transcription and real time PCR (Fig. 4.2A). The results were in line with 
expectations; miR-376b was downregulated about 6 fold in the CSC 
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population and miR-467b was downregulated about 3 fold. Both results were 
statistically significant. Furthermore, we studied the expression of these two 
miRNAs in normal mammary stem cell (MRU), progenitor (Ma-CFC) and 
differentiated epithelia cell (MEC). Both miRNAs are overexpressed in normal 
cells than that in cancer cells. In addition, both miRNAs are downregulated in 
normal mammary stem cell and progenitor populations (Fig. 4.2A). The 
highest expression of both miRNAs was seen in differentiated mammary 
epithelial cells.  
Targets of miR-376b and miR-467b. Bioinformatics analysis of the 
potential gene targets of miR-376b and miR-467b yielded several oncogenes 
and "stemness"-related genes (Table 4.3). Inhibitors of apoptosis cIAP1 and 
cIAP2 (also known as Birc2 and Birc3 respectively) were chosen for further 
study. Reverse bioinformatics confirmed that miR-376 could target cIAP1 and 
that cIAP2 could be targeted by miR-467b. The expression of cIAP1 and 
cIAP2, the potential targets of these miRNAs, was examined. Corresponding 
to the low expression of miR-376b and miR-467b, cIAP1 and cIAP2 were 
expressed higher in CSC as compared to CnSC (Fig 4.2B). Upon treatment of 
precursor miRNA molecules, the mRNA levels of each gene following 
precursor miRNA treatment were measured using real time PCR. cIAP1 
mRNA decreased about 50% upon treatment with pre-miR-376b. pre-miR-
467b had a similar effect on tumor cells decreased upon treatment with pre-
miR-376b. The effect of pre-miR-467b was not as profound (Fig. 4.3B). 
To directly prove the regulation of miRNAs to cIAPs, we use luciferase 
assays. We made luciferase expression vectors with either normal or mutated 
3’UTRs of the putative target genes. Transfection of Luc-3’UTR and pre-miR 
molecules into tumor cells, and subsequent luciferase measurement  
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   Table 4.2 Upregulation and downregulation of miRNAs in the CSC.  
 
 
 
 
 
 
 miRNA 
Fold Change 
(CSC over 
CnSC) 
p-value * 
Significantly 
upregulated 
miRNA 
 
mmu-miR-19a 
mmu-miR-9a 
mmu-miR-183 
mmu-miR-30e 
mmu-miR-29c 
5.47 
4.17 
4.09 
3.90 
3.86 
0.086 
0.040 
0.032 
0.24 
0.028 
Significantly 
downregulated 
miRNA 
 
mmu-miR-698 
mmu-miR-485 
mmu-miR-207 
mmu-miR-467b 
mmu-miR-376b 
-4.073 
-4.92 
-4.96 
-5.28 
-7.37 
0.125 
0.129 
0.100 
0.066 
0.041 
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Table 4.3 List of genes targeted by miR-376b and miR-467b. 
 
 
 
 
 
miRNA Targets Function of these target genes 
miR-376b 
Sox21/6/11/9 Stemness regulatory transcription factor 
Klf4/6 Stemness regulatory transcription factor 
cIAP1 (Birc2) Inhibitor of Apoptosis 1 
TGFβ Receptor 1 Proliferative transduction pathway 
Rab11a Oncogene 
Met Oncogene 
miR-467b 
Histone Deacetylase 9 Downregulates gene expression 
Wnt3a Promotes proliferation 
cIAP2 Inhibitor of Apoptosis 2 
E2F2 Proliferative Transcription Factor 
FoxP2 Oncogene 
Sox2 Stemness regulatory transcription factor 
Klf9 Stemness regulatory transcription factor 
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Figure 4.12 Expression of miR-376b and miR-467b in CSC and mammary 
stem cells (MaSC).  
A. Stem-loop reverse transcription qPCR illustrates that miR-376b and miR-
467b are downregulated in the CSC population (P=0.0012 and P=0.0073, 
respectively), as compared to cancer non stem cells (CnSC). When comparing 
the expression of miR-376b and miR-467b in normal mammary epithelial cells 
(MEC), mammary progenitors (Ma-CFC) and mammary stem cells (MRU), 
expression of miR-376b and miR-467b is lowest in MRU and Ma-CFC 
populations (P=0.0024 and P=0.0089, respectively). B. Expression of cIAP1 
and cIAP2 is much higher in CSC than in CnSC (P=0.0001 and P=0.0012, 
respectively). * P<0.05. R.U., Relative Units. n = 4. Mean ± SD. 
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supported the observation that miR-376b and miR-467b target the 3’UTRs of 
cIAP2. Interestingly, miR-376b treatment also decreased cIAP2 mRNA by 
about 20%. In addition, miR-467b treatment also affected cIAP1 mRNA levels, 
decreasing its expression by the same magnitude as miR-376b (Fig. 4.3A). 
Using western blotting, we observed that the cIAP1 protein was decreased 
after miR-376b treatment (Fig. 4.3B). According to luciferase assays (Fig 4.3C 
and D), the downregulation was observed with pre-miR-376b on both cIAP1 
and cIAP2. This 50% to 60% decrease in luciferase expression in cIAP1 and 
cIAP2 upon treatment with miR-376b indicates that these genes possess miR-
376b recognition sites. pre-miR-467b only caused a significant decrease in 
luciferase expression in cIAP2. These results indicate that the miRNAs of 
interest possess overlapping gene targets.  
Role of miR-376b/467b and cIAPs pathway in CSC and CnSC. To 
assess potential role of miR-376b/467b and cIAPs pathway in CSC self-
renewal, we used mammosphere formation assay. Mammosphere formation 
CSC was significantly inhibited by either pre-miR-376b, or pre-miR-467b, or 
both miRNAs. Both miRNAs treatments had cooperative effect on reducing 
mammosphere formation by CSC (Fig 4.4A). Similarly, knocking down either 
cIAP1, or cIAP2, or both genes, decreased mammosphere formation. (Fig 
4.4A). 
To further investigate the mechanism of mammosphere formation 
decreasing by miR-376b/467b and cIAPs pathway, we checked cell 
proliferation and apoptosis of CSC and CnSC. Proliferation of CSC and CnSC 
was significantly inhibited by either pre-miR-376b, or pre-miR-467b, or both, 
as measured by BrdU incorporation. Both miRNAs treatment have cooperative 
effect on decreasing cell proliferation (Fig 4.4B). Correspondingly, knock down  
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Figure 4.13 miR-376b and miR-467b directly target cIAPs.  
A. As compared to negative control, miR-376b and miR-467b decrease the 
mRNA amount of cIAP1 (P=0.004 and P=0.0041, respectively) and cIAP2 
(P=0.018 and P=0.0088, respectively) in p53 deficient MCN1 cancer cell line.  
B. Both miR-376b and miR-467b decrease levels of cIAP1 protein. C.D. 
Luciferase assay results of MCN1 (p53-/-) cancer cells transfected with 
vectors (0.4 µg) and pre-miRNA molecule (20 nM). Vector cIAP1 N has 
predicted miR-376b binding seed sequence in 3’-UTR of cIAP1, and cIAP2 N 
has predicted miR-467b binding seed sequence in 3’-UTR of cIAP2. Vectors 
(cIAP1 M and cIAP2 M) have mutated miRNA binding sequences. miR-376b 
specifically inhibit expression of cIAP1 (P=0.0039), while both miR-376b and 
miR-467b can inhibit expression of cIAP2 (P=0.0018 and P=0.0056, 
respectively). R.U., Relative Luciferase Units. * P<0.05. N=3. Mean ± SD.  
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of the either cIAP1, or cIAP2, or both genes, decreased proliferation of both 
CSC and CnSC. Interestingly, miRNAs treatments had  more apparent effects 
on CSC and CnSC proliferation than downregulation of cIAP1 and cIAP2, 
indicating that other targets of miRNAs contributed to the cell proliferation 
decreasing (Fig 4.4B).According to staining for the apoptosis marker cleaved 
caspase-3, after  treatment with either pre-miR-376b, or pre-miR-467b, or both 
miRNAs, CSC and CnSC apoptosis was lowest in the cells treated with 
scrambled miRNA (negative control), which is biologically inert. The highest 
rate of apoptosis in CSC and CnSC was observed in cells treated with both 
pre-miR-376b and pre-miR-467b (Fig. 4.4C). Consistently, knock down of 
either cIAP1, or cIAP2, or both genes, led to increase in CSC and CnSC 
apoptosis. The highest rate of apoptosis in CSC and CnSC was observed in 
cells with both cIAP1 and cIAP2 knockdown (Fig. 4.4C). Taken together, these 
results demonstrate that effects of miR-376b and miR-467b on increasing cell 
proliferation and decreasing cell apoptosis may go through the cIAP1 and 
cIAP2 pathway.  
 
4.5 Discussion 
miR-376b and miR-467b were significantly downregulated in CSC. We 
have proved that cIAP1 and cIAP2 are among their downstream targets. 
These two inhibitors of apoptosis (IAP) family members were upregulated in 
CSCs and show parallel upregulation in the Ma-CFCs. IAP family consists of 
eight members, which collude to suppress apoptosis by directly inhibiting both 
initiator and effector caspase activity. The defining characteristic of IAPs is a 
baculovirus IAP repeat (BIR) domain, which is directly involved in caspase 
inhibition. We have demonstrated in Chapter 2 that downregulation of cIAP1  
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Figure 4.14 Effects of miR-376b, miR-467b and cIAPs on CSC.   
Primary p53 deficient cancer cells were treated with either miR-376b or miR-
467b, or cIAPs, and then sorted for CSC and CnSC. A. Culturing the CSC 
mammosphere demonstrated that both miR-376b and miR-467b treatments 
decrease the mammosphere formation (P=0.0012 and P=0.048, respectively), 
while miR-376 has the most significant effect. Both siR-cIAP1 and siR-cIAP2 
treatments decrease the mammosphere formation (P=0.024 and P=0.0026, 
respectively), and knocking down both cIAP1 and cIAP2 has cooperative 
effect on mammosphere formation (P=0.0004). B. Significant decreases of cell 
proliferation were observed in CnSC treated with miR-376b (P=0.0225), miR-
467b (P=0.0097) and both miRNAs (P=0.0083) and in CSC treated with miR-
376b (P=0.0011), miR-467b (P=0.0128) and both miRNAs (P=0.0001). 
Significant decreases of cell proliferation were observed in CnSC treated with 
siR-cIAP1 (P=0.042), miR-467b (P=0.038) and both miRNAs (P=0.0283) and 
in CSC treated with miR-376b (P=0.048), miR-467b (P=0.0428) and both 
miRNAs (P=0.0189). C. Significant increases of cell apoptosis were observed 
in CnSC treated with miR-376b (P=0.0024), miR-467b (P=0.0073), and both 
were observed in CnSC treated with siR-cIAP1 (P=0.018), miR-467b 
(P=0.013), and both miRNAs (P=0.0023) and in CSC treated with miR-376b 
(P=0.012), miR-467b (P=0.018) and both miRNAs (P=0.037). *P<0.05. R.U., 
Relative Units. N= 3. Mean ± SD.  
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and cIAP2 is able to decrease cell proliferation and increase apoptosis.  
Elevated levels of cIAPs are fairly common in cancer cells, and in some 
models, is a requisite step in the initiation of transformation. In brain tumor 
stem cells, it was observed that elevated levels of cIAPs correlated with 
multidrug and chemotherapeutic resistance (Liu et al., 2006). 
miR-376b has a mature sequence of 
5’AUCAUAGAGGAACAUCCACUU 3’ (seed sequence given in bold). miR-
376b is a member of a large cluster of 40 miRNAs that is found on 
chromosome 12 in Mus musculus and conserved on Homo sapiens 
chromosome 14.q32.31. The human version of miR-376b maintains the same 
seed sequence as in the mouse, but has different nucleotides at the 3’ end. 
Furthermore, this cluster appears to be imprinted to the maternal 
chromosome, with little or no expression of genes from the paternal 
chromosome (Lin et al., 2003). It is expected that this cluster is expressed 
under control of the neighboring Gtl2 promoter as a poly-cistronic primary 
transcript. Gtl2 is known to be actively transcribed in embryos, providing a 
contextual clue that the miRNA cluster, which includes miR-376b and would 
most likely be co-expressed with Gtl2, plays a role in regulating embryonic 
development (Seitz et al., 2004). Deletion of maternal imprinting results in 
embryonic lethality, emphasizing the importance of the genes controlled under 
the maternal Gtl2 promoter. Parallel to this observation, paternal uniparental 
disomy 12 are also embryonic lethal since the Gtl2 promoter is methylated and 
therefore inhibited (Schuster-Gossler et al., 1998). It was shown that miR-376b 
is expressed in mouse embryos, and is surprisingly over-represented in 
mouse teratocarcinomas. Furthermore, the seed sequence, as mentioned 
earlier, is conserved between mice, rats, and humans (Landgraf et al., 2007).  
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miR-467b has a mature sequence of 5’ 
GUAAGUGCCUGCAUGUAUAUG 3’ (seed sequence given in bold). miR-
467b is part of a large cluster of about 50 miRNAs that are within the 10th 
intron of the gene Sfmbt2, which is found on mouse chromosome 2. 
Therefore, the expression of miRNA within this cluster is linked tightly to the 
expression of Sfmbt2 and the activity of its promoter and enhancers(Sun et al., 
2009). The chromosome 2 cluster has been linked with promoting self-renewal 
and pluripotence(Calabrese et al., 2007). The expression of this cluster was 
found to be highest in ES cells, but decreases upon retinoic acid-induced 
differentiation. In particular, Sox2 was proposed as a target of miR-467b, 
implicating miR-467b in a feedback loop that tightly regulates ES cell self-
renewal(Gu et al., 2008).     
Sfmbt2 is a member of the Polycomb Group (PcG) genes, which, as 
described earlier, are crucial regulators of homeobox gene expression and are 
often predictive of a CSC phenotype. It was shown that SFMBT2 forms a 
complex with the transcription factor YY1 to maintain the stem cell population 
in ES cells. Additionally, it was shown that Sfmbt2 is paternally imprinted in 
early embryonic development (Kuzmin et al., 2008), leading us to infer that the 
associated intronic miRNA cluster is also paternally imprinted. Interestingly, 
Yaf2, also known as YY1-associated factor 2, was mentioned as a putative 
target of unedited miR-376b (Kawahara et al., 2007). This suggests a complex 
loop of feedback regulation where co-expression of miR-376b and miR-467b 
results in decreased SFMBT2 activity due to inhibition of YAF2/YY1. If both 
miRNA are downregulated, as we observe in our CSCs, we would expect 
increased SFMBT2 activity, resulting in increased stem cell maintenance. This 
is one instance of many possible cross-talk pathways between miR-376b and 
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miR-467b.  
Additionally, we have shown that both pre-miR-376b and pre-miR-467b 
can induce apoptosis and inhibit proliferation in mammary carcinoma cells. We 
have demonstrated the important role of cIAP1/2 in mammary carcinogenesis 
(Chapter 2). Therefore, these observations can be attributed, in part, to the 
inhibition of cIAP1/2 translation. Reconstitution of miR-376b and miR-467b 
expression results in lower cellular concentrations of cIAP1/2 signaling. 
Therefore, downregulation of the miR-376 family may be one of the key events 
during mammary carcinogenesis in our model.  
It should be noted that the ability of CSC to form mammosphere is likely 
to be controlled by miR-376b/467b-cIAP1/2 pathway. Consistently, miR-376b 
and miR-467b expression is lowest, and cIAP1 and cIAP2 expression is 
highest in MRU and Ma-CFC, consistent with the expectation of high 
frequency of mammosphere formation in MaSC and high proliferation in their 
progeny. Apoptosis is also suppressed in stem cells, consistent with our 
hypothesis, which suggests that cIAP1 and cIAP2 are upregulated, in part, due 
to the decrease in their negative regulator miR-376b and miR-467b.  
These observations would allow us to draw parallels between miR-
376b/467b and miR-15/16. These miRNAs target the anti-apoptotic protein 
Bcl2. Absence of these miRNA leads to a decrease in the rate of apoptosis, 
resulting in a massive expansion of the B cell population. We observe that in 
our model of mammary cancer, associated with p53 and/or Rb deficiency, 
there is a decrease in miR-376b and miR-467b expression in CSCs. 
Consequently, increased levels of cIAP1 and cIAP2 result in decreased 
apoptosis, which has been correlated to irradiation resistance, consistent with 
previously established theories of CSCs.  
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Taken together, the above studies indicate that the CSC phenotype 
may be, in part, due to lower expression of miR-376b and miR-467b and high 
expression of cIAP1 and cIAP2. The connections between the primary 
mutations, loss of p53 and Rb, and the downstream observation that miR-
376b and miR-467b are specifically downregulated in the CSCs, remain to be 
elucidated. It is unclear if loss of p53 and Rb directly influences the expression 
of miR-376b and miR-467b. Rather, p53 and Rb loss may occur in cells that 
already maintain low expression of these two miRNA (as shown by real time 
PCR of wild type MRU and Ma-CFC) in order to preserve stemness. In this 
case, the tumorigenic effect of p53 and Rb loss, in conjunction with the 
previously existent stem cell gene expression profile, results in the formation 
of CSC. If this hypothesis is true, then it would not be unexpected to find 
downregulation of miR-376b and miR-467b in other putative stem cell and 
CSC models.  
As described earlier, it is imperative to focus on treating not only rapidly 
dividing cells, but also the relatively quiescent CSC that are capable of 
metastasizing and seeding new tumors. If miR-376b and miR-467b directly 
inhibit stemness, proliferative, and anti-apoptotic genes, reconstitution of their 
expression can be a vital biological approach to treating CSC. Furthermore, 
chemical inhibitors of IAP family proteins have been a recent area of focus. 
These drugs hold great promise in promoting apoptosis in conjunction with 
ionizing radiation treatment or chemotherapy (LaCasse et al., 2008). Thus, our 
studies provide an essential basis for development of CSC-specific therapeutic 
approaches targeting 376b/ miR-467b - cIAP1/2 pathway.  
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CHAPTER 5 
 
SUMMARY 
 
5.1 Summary of findings 
We generated MMTV-Cre105Ayn mice to inactivate p53 and/or Rb 
strictly in the mammary epithelium and determined recurrent genomic changes 
associated with deficiencies of these genes. p53 inactivation led to formation 
of estrogen receptor positive raloxifene-responsive mammary carcinomas with 
features of luminal subtype B. Rb deficiency was insufficient to initiate 
carcinogenesis but promoted genomic instability and growth rate of neoplasms 
associated with p53 inactivation. Genome-wide analysis of mammary 
carcinomas by aCGH identified a recurrent amplification at chromosome band 
9qA1, a locus orthologous to human 11q22, which contains protooncogenes 
cIAP1, cIAP2 and Yap1. Interestingly, this amplicon was preferentially 
detected in carcinomas carrying wild-type Rb. However, all three genes were 
overexpressed in carcinomas with p53 and Rb inactivation, likely due to E2F-
mediated transactivation and cooperated in carcinogenesis according to gene 
knockdown experiments. In addition, knock-down of cIAP1, cIAP2 and Yap1, 
has cooperative effects on decreasing cell proliferation and increasing cell 
apoptosis  in cell culture, and slowing down the tumor growth in vivo. These 
findings establish a mouse model of human luminal subtype B mammary 
carcinoma, identify critical role of cIAP1, cIAP2 and Yap co-expression in 
mammary carcinogenesis and provide an explanation for the lack of recurrent 
amplifications of cIAP1, cIAP2 and Yap1 in some tumors with frequent Rb-
deficiency, such as mammary carcinoma.  
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The cancer stem cells (CSC) hypothesis postulates that tumors are 
maintained by a population of neoplastic cells with stem cell properties such 
as the ability to self-renew and to produce a progenitor cell that can proliferate 
and differentiate, presumably after one asymmetric cell division (Wicha et al., 
2006). We have isolated CSC from a mouse model of mammary carcinoma  
associated with p53 and/or Rb deficiency by using the mammary stem cell 
markers CD24 and CD49f. CSC have higher frequency of colony formation in  
Matrigel, exhibited higher tumorigeneicity and were able to reconstitute all 
tumor cell populations after serial orthotopic transplantations as compared to 
CnSC. Our studies also determined that CSC have higher level genomic 
stability and exhibit less of DNA damage as compared to CnSC. We have also 
studied the role of mammary stem cells in carcinogenesis, and found that loss 
of either p53 or Rb leads to an increase in the number and proliferation rate of 
Ma-CFCs (mammary progenitor cells) but not MRUs (mammary stem cells). 
Both parameters are further increased in Ma-CFC pool deficient for both p53 
and Rb. The mammary progenitor cells may be the principle targets for 
malignant transformation, and suggest expansion of progenitor cell pool as a 
novel cooperative effect of p53 and Rb inactivation on carcinogenesis. 
Finally, microarray analysis have identified miR-376b and miR-467b as 
the most downregulated miRNAs in both CSC and mammary stem cells, as 
compared to CnSC and normal differentiated mammary epithelial cells. Using 
bioinformatics and luciferase reporter assay, we have determined that cIAP1 
and cIAP2 proto-oncogenes as targets of both miRNAs. It has been further 
demonstrated  that cIAP1/2 are overexpressed in CSC as compared to CnSC, 
and miR-376b and miR-467b reconstitution leads to decreased levels of 
cIAP1/2 according to quantitative RT-PCR and western blotting. Luciferase 
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reporter assay has directly confirmed that miR-376b and miR-467b may 
regulate cIAP1/2 expression. Accordingly, miR-376b and miR-467b 
reconstitution, as well as cIAP1/2 siRNA-mediated knockdown decrease the 
mammosphere formation from CSC, inhibiting cell proliferation and promote 
cell apoptosis. These studies indicate that miR-376b/ miR-467b - cIAP1/2 
pathway is important for CSC function and may represent a new target for 
development of new therapeutic approaches. 
In summary (Fig 5.1), our studies have demonstrated that deregulation 
of miR-376b/miR-467b-cIAP1/2 pathway has an important role in mammary 
carcinoma associated with p53 or p53 and Rb deficiency. Overexpression of 
cIAP1/2 is ensured by gene amplification in neoplasms associated with p53 
deficiency. Rb loss induces transcription factor E2F expression, which 
transactivates cIAP1 and cIAP2 expression, thereby eliminating the need for 
amplification of these genes. Additionally, mammary carcinomas have 
decreased levels of miR-376b/miR-467b, which have been proven to directly 
suppress expression of cIAP1/2. At least a part of miR-376b/miR-467b-
cIAP1/2 pathway's effects on carcinogenesis may be explained by its role in 
self-renewal of CSC. It should be noted that cIAP1/2 are negative regulators of 
both classic and alternative NF-κB signaling (Mahoney et al., 2008), which has 
a key role in many physiological processes, including cell proliferation, 
differentiation, death, and inflammation, etc (Baud and Karin, 2009). It is 
known that p53 induces differentiation of mouse embryonic stem cells by 
suppressing Nanog expression (Lin et al., 2005). Nanog maintains 
pluripotency of mouse embryonic stem cells by inhibiting NF-κB (Torres and 
Watt, 2008). As discussed below, involvement of NF-κB in CSC will be 
explored in the future.   
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Figure 5.15 Proposed model for miR-376b/miR-467b-cIAP1/2 pathway in 
mammary carcinogenesis. 
p53 loss leads to cIAP1/2 DNA copy number increase, which causes the 
overexpression of cIAP1/2. Rb loss leads to E2F expression, which 
transactives cIAP1/2. miR-376b/miR-467b are downregulated in mammary 
carcinoma associated with p53 and/or Rb inactivation. cIAP1/2 are 
downregulated by miR-376b/miR-467b. miR-376b/miR-467b and cIAP1/2 are 
likely involved in regulation of CSC self-renewal. NF-κB signaling may be the 
downstream target of miR376b/467b-cIAP1/2 pathway. 
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5.2 Future research 
Further characterization of CSC. Our experiments have 
demonstrated that mammary carcinomas can be reproducibly initiated by p53 
inactivation alone and their formation can be accelerated by inactivation of Rb.  
Our studies also demonstrated presence of CSC in these tumors and 
indicated that these cells express high levels cIAP1 as compared to CnSC and 
all types of cells in the normal mammary epithelium. Based on these 
observations we intend to identify CSC at sequential stages of mammary 
carcinogenesis and determine time of appearance of cIAP1 expressing cells 
by standard immunohistochemistry analysis. In addition, we intend to 
investigate properties of CSC, such as their proximity to the invasive front of 
tumor and vessels, their motility, proliferation and apoptosis and response to 
hypoxia, and chemotherapeutic agents.  
Further study of the connection between expanded mutant 
mammary progenitor (Ma-CFC) and CSC. In chapter 3, we identified and 
characterized CSC, and also found that expansion of mammary precursor 
cells (Ma-CFC) but not stem cells (MRU) in development of mammary 
neoplasms associated with p53 and/or Rb deficiency. One of interesting 
questions that has not yet been answered is the relationship of expanded Ma-
CFC population and CSC. Are Ma-CFC the cell origin of CSC? The limitation 
of the current mouse model for addressing this question is low efficiency of 
Cre-mediated recombination in MRU and Ma-CFC. Only 2.8% of MRU and 
3.4% of Ma-CFC have Cre expression. Therefore we intend to use additional 
available lines of MMTV-Cre transgenic mice, such as MMTV-Cre line F 
(Wagner et al., 1997). According to our preliminary results around 50% Ma-
CFC and MRU have Cre expression in this line. As a future additional 
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important tool, mice with temporal regulation of Cre are planned to be 
generated. By using crosses of these MMTV-Cre mice with p53L/L, RbL/L and 
p53L/LRbL/L mice, it should be possible to further investigate roles of p53 and 
Rb in control of mammary stem and progenitor cells and to determine if 
expanded pool of mutant Ma-CFC gives rise to CSC. 
Investigation of mechanism of E2F-mediated regulation of cIAP1, 
cIAP2 and Yap1, and p53-mediated regulation of Yap1. Our results in 
Chapter 2 demonstrated that knock down of E2F leads to the decrease of 
cIAP1, cIAP2 and Yap1 expression. According to bioinformatics, the promoter 
regions of these genes have E2F binding sites. It would be important to 
confirm if this is the mechanism of E2F-mediated regulation of cIAP1, cIAP2 
and Yap1. To that end we are going to use Chromatin immunoprecipitation 
(ChIP) assay, which is a powerful tool for identifying proteins associated with 
specific regions of the genome by using specific antibodies that recognize a 
specific protein. In addition, according to computational analysis, Yap1 intron 1 
contains 100% matching p53 binding site. Consistently, decrease and 
increase of Yap1 expression is observed after p53 deletion and doxorubicin-
induced p53 upregulation, respectively. It will be of particular interest to 
identify mechanisms substituting for p53-mediated Yap1 transcriptional 
activation in p53 deficient tumors. Answers to these questions will help us 
further understand the mechanisms of mammary carcinogenesis associated 
with p53 and Rb inactivation. 
Mechanism of chemoresistance and radioresistence of CSC. 
Recent studies have shown that CSC are resistant to chemo- and radiation 
therapy (An and Ongkeko, 2009; Bao et al., 2006; Chiou et al., 2008). It has 
also been demonstrated that overexpression of cIAP1 causes resistance to 
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drug treatments in certain types of breast cancer (Wang et al., 2009). As 
discussed in the dissertation, we found that overexpression of cIAP1 is 
associated with downregulation of miR-376b. Therefore, we want to test if the 
resistance of CSC to therapy is due to the overexpression of cIAP1 and/or 
downregulation of miR-376b. The simple test will be knockdown the cIAP1 
expression or reconstitute miR-376b in CSC, treat CSC with therapeutic drugs 
or γ irradiation, and determine if downregulation of cIAP1 or normalization of 
miR-376b levels sensitizes CSC to chemo- and radiation therapy. 
Furthermore, to make our model even more relevant to human cancer, we are 
going to isolate CSC from these cell human breast cancer cell lines, and check 
cIAP1 and miR-376b expression. High expressing cIAP1 and low expressing 
miR-376b cell lines will be selected for chemo- and radiation treatments, and 
the response of CSC to therapeutic drugs or irradiation with or without cIAP1 
knockdown or pre-miR-376b treatment will be compared.  
Effects of cIAP1 overexpression and deficiency on regulation of 
normal mammary stem, progenitor and differentiated cells, as well as 
CSC and CnSC in vivo. Our results demonstrated that recurrent amplification 
of human cancer-related genes cIAP1, cIAP2 and Yap was detected in mouse 
mammary carcinomas associated with inactivation of p53 alone or together 
with Rb. Notably these genes are upregulated specifically in cancer stem cells. 
Effects of cIAP1 deficiency on regulation of CSC have been studied in cell 
culture. We need to further study the deficiency of cIAP1 in normal mammary 
stem, progenitor and differentiated cells. To evaluate effects of cIAP1 on 
regulation of all these cells in vivo, we plan to use mice deficient for cIAP1 and 
cIAP2. We also propose to test if overexpression of these genes may 
represent an early and essential step towards selection of a subset of highly 
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tumorigenic CSC. 
To evaluate effects of cIAP1 deficiency, mammary epithelial cells 
carrying inactivated cIAP1 will be isolated from young (60 days old) female 
mice resulting from crosses of p53ME-/-Rb ME-/- mice with cIAP1 -/- mice and 
either processed for cell isolation followed by FACS and/or cell culture or 
directly implanted into cleared mammary fat pad. At the same time, mammary 
cells of p53 floxP/floxPRbfloxP/floxP mice and p53floxP/floPxRbfloxP/floxP cIAP1-/- mice will 
be initially isolated, placed in cell culture or sorted with FACS and exposed to 
either AdCMVCre or lentivirus Cre. After each approach, cells will be tested for 
proliferation, survival, self-renewal, senescence, differentiation and malignant 
transformation. Furthermore, effects of cIAP1 overexpression will be studied 
by introduction of cIAP1 expression constructs into primary mammary cells 
sorted for stem cell markers. Furthermore, transgenic mice with conditional 
expression of cIAP1will be generated and crossed to p53 ME-/- and/or Rb ME-/- 
mice and effect of cIAP1 on progression and metastasis of mammary 
neoplasms in the context of either p53 or Rb deficiency will be established. 
Further study of the function of miR-376b and miR467b in 
mammary stem cells and CSC self-renewal. The role of miR-376b and miR-
467b in MaSC and CSC, especially in in vivo has not been fully addressed in 
my study. To fill this void, MaSC and CSC will be infected with microRNA 
lentivirus vector, which can continuously express miR-376b and/or miR-467b. 
Infected MaSC or CSC will then be transplanted to cleared mammary fat pad 
to observe the effects of these miRNAs on either mammary gland tree 
formation or mammary carcinoma formation. MaSC and CSC from transplant 
tissues will be separated by FACS sorting to have the second and third round 
transplantation. We predict that these miRNAs could delay or reduce the 
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ability of MaSC to form mammary gland tree, and could affect CSC form 
mammary carcinoma in vivo. If these expectations have been met, generation 
of mice carrying floxed copies of miR-376b and miR-467b will be initiated. 
Role of NF-κB signaling pathway in CSC regulation. Recently, it has 
been shown that cIAP1/2 are negative regulators of both classic and 
alternative NF-κB signaling (Mahoney et al., 2008). Our results have shown 
overexpression of cIAP1/2 preferential overexpression of cIAP1/2 in CSC, but 
role of NF-κB signaling in CSC remains unknown. NF-κB signaling pathway is 
often altered in human cancers, including both solid and hematopoietic 
malignances (Baud and Karin, 2009). NF-κB pathway is involved in diverse 
biological processes, including embryo development, hematopoiesis, immune 
regulation, and neuronal functions through the transcriptional activation of 
genes associated with these processes (Baud and Karin, 2009). In addition, it 
has been found that Nanog maintains pluripotency of mouse embryonic stem 
cells by inhibiting NF-kB (Torres and Watt, 2008), and the activity of NF-κB is 
increased during differentiation of embryonic stem cells (Kim et al., 2008). 
Activation of NF-κB could trigger the proliferation of adult neural stem cells 
(Widera et al., 2006). Therefore, it is of interest to determine if NF-κB signaling 
plays a role in CSC regulation.  
First of all, we will study the NF-κB activity in CSC as compared to 
CnSC. If the result is consistent with our predication, we will further investigate 
the role of NF-κB in CSC self-renewal by either knocking down or 
overexpressing individual components of NF-κB pathway in cell culture and in 
vivo experiments. 
 158 
REFERENCES 
 
An, Y., and Ongkeko, W. M. (2009). ABCG2: the key to chemoresistance in 
cancer stem cells? Expert Opin Drug Metab Toxicol 5, 1529-1542. 
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., 
Dewhirst, M. W., Bigner, D. D., and Rich, J. N. (2006). Glioma stem cells 
promote radioresistance by preferential activation of the DNA damage 
response. Nature 444, 756-760. 
Baud, V., and Karin, M. (2009). Is NF-kappaB a good target for cancer 
therapy? Hopes and pitfalls. Nat Rev Drug Discov 8, 33-40. 
Chiou, S. H., Kao, C. L., Chen, Y. W., Chien, C. S., Hung, S. C., Lo, J. F., 
Chen, Y. J., Ku, H. H., Hsu, M. T., and Wong, T. T. (2008). Identification of 
CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS 
One 3, e2090. 
Kim, Y. E., Kang, H. B., Park, J. A., Nam, K. H., Kwon, H. J., and Lee, Y. 
(2008). Upregulation of NF-kappaB upon differentiation of mouse embryonic 
stem cells. BMB Rep 41, 705-709. 
Lin, T., Chao, C., Saito, S., Mazur, S. J., Murphy, M. E., Appella, E., and Xu, 
Y. (2005). p53 induces differentiation of mouse embryonic stem cells by 
suppressing Nanog expression. Nat Cell Biol 7, 165-171. 
Mahoney, D. J., Cheung, H. H., Mrad, R. L., Plenchette, S., Simard, C., 
Enwere, E., Arora, V., Mak, T. W., Lacasse, E. C., Waring, J., and Korneluk, 
R. G. (2008). Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB 
activation. Proc Natl Acad Sci U S A 105, 11778-11783. 
Torres, J., and Watt, F. M. (2008). Nanog maintains pluripotency of mouse 
 159 
embryonic stem cells by inhibiting NFkappaB and cooperating with Stat3. Nat 
Cell Biol 10, 194-201. 
Wagner, K. U., Wall, R. J., St-Onge, L., Gruss, P., Wynshaw-Boris, A., Garrett, 
L., Li, M., Furth, P. A., and Hennighausen, L. (1997). Cre-mediated gene 
deletion in the mammary gland. Nucleic Acids Res 25, 4323-4330. 
Wang, M. Y., Chen, P. S., Prakash, E., Hsu, H. C., Huang, H. Y., Lin, M. T., 
Chang, K. J., and Kuo, M. L. (2009). Connective tissue growth factor confers 
drug resistance in breast cancer through concomitant up-regulation of Bcl-xL 
and cIAP1. Cancer Res 69, 3482-3491. 
Wicha, M. S., Liu, S., and Dontu, G. (2006). Cancer stem cells: an old idea--a 
paradigm shift. Cancer Res 66, 1883-1890; discussion 1895-1886. 
Widera, D., Mikenberg, I., Elvers, M., Kaltschmidt, C., and Kaltschmidt, B. 
(2006). Tumor necrosis factor alpha triggers proliferation of adult neural stem 
cells via IKK/NF-kappaB signaling. BMC Neurosci 7, 64. 
 
 
 
